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Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common 
cancer worldwide. In 2005, the American Cancer Society estimates that 29,370 new cases of 
oropharyngeal tumors will occur in the United States, accounting for 2.1 % of new cancer cases 
and 1.3% of cancer deaths.  Squamous cell carcinoma of the head and neck and its subset, oral 
squamous cell carcinoma (OSCC), arise from a combination of environmental factors and 
genetic events.  Although high-risk behaviors such as smoking cigarettes, using smokeless 
tobacco, and consuming excessive alcohol have been shown to play a role in OSCC development 
in many individuals, oral cancer has also been observed in people with no apparent history of 
tobacco or alcohol use. Unfortunately, more than 60% of patients identified as having SCCHN 
are diagnosed after reaching an advanced stage of the disease.  As a result of late-stage tumor 
discovery, the overall survival rate for affected individuals is less than 50%, and remains one of 
the lowest when compared to other major cancer types. 
One ongoing problem with treating OSCC is that tumors from the same site within the 
oral cavity respond differently to identical treatment regimens.   This is due in part to OSCC 
expressing chromosomal instability (CIN), in which karyotypes vary from cell to cell.  CIN may 
then promote survival of subpopulations within a given tumor.  In an effort to determine a 
mechanism for the development and/or progression of OSCC, we first examined the 
chromosomal content of cloned cell populations isolated from two OSCC cell lines.  We showed 
that no two cells from the original parent or subsequent daughter clones in either cell line 
expressed the identical karyotype, confirming the presence of CIN in OSCC.   
Various ways in which CIN may arise in tumor cells include: 1) faulty mitotic apparatus 
machinery, 2) centrosome amplification, 3) telomere dysfunction, 4) defects in the DNA damage 
response, and 5) gene amplification.  Previous studies from our laboratory identified 11q13 gene 
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amplification in the form of a homogeneously staining region (hsr) in approximately 45% of our 
OSCC cell lines.  FISH analyses using probes for the RIN1 and CCND1 genes demonstrated an 
inverted duplication pattern within the 11q13 amplicon, suggesting a BFB cycle model for gene 
amplification.  In order to confirm that BFB cycles lead to gene amplification, a form of CIN in 
our OSCC cells, we examined dividing cells from 29 OSCC cell lines for the presence of the 
inverted duplication pattern within anaphase bridges, which are known BFB cycle intermediates. 
We show that the inverted duplication pattern occurred in a higher frequency of anaphase bridges 
expressed by OSCC cell lines with 11q13 amplification compared to OSCC cell lines without 
11q13 amplification. By demonstrating the inverted duplication pattern within anaphase bridges, 
we provide evidence that at least some cases of gene amplification expressed in the form of an 
hsr occur through the BFB cycle mechanism in OSCC cells.  Furthermore, we show that hsrs 
within cells are heterogeneous, consistent with the suggestion that variations in the size of the 
amplicon are determined by the site of breakage (Toledo et al. 1992), a form of CIN that may 
also be explained by the BFB model of gene amplification.     
We next set out to determine a mechanism by which gene amplification is initiated in 
OSCC cells.  Recent reports have suggested that gene amplification in the form of a 
homogeneously staining region (hsr) may result from breaks in common fragile sites (CFS),  
sensitive regions of the genome which may form gaps or breaks in metaphase chromosomes 
when cells are grown under conditions that interfere with DNA replication or repair.  Previous 
studies from our laboratory identified proximal and distal breakpoint regions relative to the 
11q13 amplicon.  We propose that common fragile sites in chromosome 11 may be located 1) 
between the RIN1 and CCND1 genes and 2) distal to the CCND1 gene, and may play a role in 
chromosome breakage and subsequent gene amplification through BFB cycles.  We mapped the 
CFS, FRA11F, to a 7.5 Mb region distal to the 11q13 amplicon at 11q14.2, and identified the 
DNA sequence that corresponds to it.  OSCC cell lines expressing 11q13 amplification had loss 
of FRA11F sequences, while the FRA11F regions within cell lines without the 11q13 amplicon 
were not associated with distal chromosome loss or rearrangement.  In OSCC cells containing 
more complex rearrangements of 11q, FRA11F sequences appeared to localize within the 11q13 
amplicon.  FRA11F was not only broken between its proximal and distal sequences in complex 
rearrangements, but also displayed the inverted duplication pattern we previously identified in 
the 11q13 amplicon using probes for RIN1 and CCND1.   
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Combined, our findings demonstrate that 11q13 gene amplification in OSCC occurs 
through BFB cycles, and suggest that breakage or loss of FRA11F may play a key role in 
initiating 11q13 amplification.  Further insight into the mechanisms initiating and promoting 
gene amplification will provide opportunities to identify new biomarkers to aid in diagnosis and 
prognosis of oral cancer and other cancers, and may be of use for developing novel therapeutic 
strategies for patients with SCCHN. 
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PUBLIC HEALTH RELEVANCE 
 
 
 In the United States, cancer is a leading cause of death, second only to heart disease 
(MOKDAD et al. 2004).  A study in the Journal of the American Medical Association reported 
tobacco, poor diet, lack of physical activity, and alcohol consumption as the top four of risk 
factors associated with death in the United States (MCGINNIS and FOEGE 1993).   Although it is 
estimated that in 2005, cancer of the oral cavity will account for only 2.1% of cancer cases and 
1.3% of overall cancer deaths in the U. S. (JEMAL et al. 2005), high-risk behaviors such as 
smoking cigarettes, using smokeless tobacco, and consuming excessive alcohol have been shown 
to play a major role in OSCC development.   
Exposure to environmental agents, including tobacco smoke, smokeless tobacco, 
alcoholic beverages, and/or viruses, such as human papillomavirus (FORASTIERE et al. 2001; HO 
and CALIFANO 2004; MORK et al. 2001) have a profound influence on cells within the oral 
cavity.  These factors have been shown to induce genetic alterations including chromosomal 
alterations, DNA changes (eg. mutations, amplifications or deletions), and/or epigenetic 
alterations, such as changes in DNA methylation that affect genetic regulation.  Genetic 
alterations in cells are useful biological markers that assist in early detection of cancer and 
response to therapy (SIDRANSKY 1995).  Currently, however, there are no useful biomarkers to 
identify early changes involved in OSCC development.  As a result, affected individuals are 
diagnosed late and have a survival rate of less than 50%, which remains one of the lowest when 
compared to other major cancer types. 
One specific genetic alteration observed in 45% of OSCC is amplification of 
chromosomal band, 11q13.  This event has been shown to follow dysplastic cellular changes, but 
occur prior to development of carcinoma in situ (FORASTIERE et al. 2001).  Therefore, 11q13 
amplification may be a useful biomarker for detecting OSCC.  In addition, understanding the 
molecular mechanisms that promote 11q13 gene amplification may provide valuable information 
for devising novel prevention measures and therapies.  In the current study, we show that the 
primary mechanism promoting 11q13 gene amplification is BFB cycles.  Furthermore, we 
suggest that breakage at the common fragile site, FRA11F, may be responsible for initiating 
11q13 gene amplification.  Taken together, using the breakage frequency of FRA11F as a 
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molecular marker for early detection of OSCC may be useful for identifying individuals who 
may be at risk for disease progression through 11q13 gene amplification.  By determining the 
primary mechanism that leads to 11q13 amplificaton in OSCC, additional investigations focusing 
on the biological basis of this process may provide important information for developing 
successful measures and treatments that will increase the survival rate for individuals afflicted 
with oral cancer.   
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1.     SPECIFIC AIMS 
 
The purpose of this study is to explore the biological mechanisms that play a role in 
chromosomal instability in oral cancer.  We and others have shown previously that karyotypes of 
OSCC cells contain near-triploid chromosome numbers and express various structural and 
numerical chromosome abnormalities (GOLLIN 2001; JIN et al. 2002). Of particular interest to 
our laboratory is the 11q13 hsr observed in 45% of OSCC cells.  The hsr form of gene 
amplification has been shown in some cases to result from breakage within regions of the 
genome expressing late replication and AT-rich strands with high flexibility, namely, common 
fragile sites (CFS). Previous investigations from our laboratory revealed that genes within the 
11q13 hsr of OSCC cells displayed an inverted duplication pattern of CCND1 flanked by RIN1, 
supporting a BFB cycle mechanism for gene amplification.  In addition, we recently identified 
proximal and distal breakpoint regions relative to the core region of the11q13 amplicon.  We 
propose that common fragile sites in chromosome 11 may be located 1) between the RIN1 and 
CCND1 genes and 2) distal to the CCND1 gene, and may play a role in chromosome breakage 
and subsequent gene amplification through BFB cycles. Therefore, we hypothesize that 11q13 
gene amplification in OSCC results from BFB cycles, and that breakage at one or more 
CFS may be the initial step in 11q13 gene amplification. This study is designed to determine 
mechanisms by which 11q13 amplification occurs in OSCC cells by fulfilling the following 
Specific Aims:  
 
1. Validate the BFB mechanism for 11q13 amplification in OSCC cells.   
2. Identify and characterize common fragile sites (CFS) on the long arm of 
chromosome 11 in normal human cells.  
3. Demonstrate a relationship between breakage “hotspots” identified as CFS and 
11q13 gene amplification in OSCC cells.  
 
The goal of this study is to define a mechanism for 11q13 gene amplification in oral 
cancer and to determine whether clustered breakpoint regions flanking the 11q13 amplicon 
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 correspond to regions harboring CFS.   Determining the major mechanism that promotes 11q13 
amplification in OSCC may 1) identify a useful biomarker for early OSCC development and/or 
OSCC progression and 2) aid in developing strategies to prevent chromosome breakage which 
may lead to gene amplification.  
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2. INTRODUCTION AND BACKGROUND 
 
 
2.1. ORAL CANCER EPIDEMIOLOGY 
 
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer 
worldwide (PARKIN et al. 1999). In 2005, the American Cancer Society estimates that 29,370 
new cases of oropharyngeal tumors will occur in the United States, accounting for 2.1% of new 
cancer cases and 1.3% of cancer deaths (JEMAL et al. 2005).  Tumors of the oral cavity, 
commonly known as oral squamous cell carcinoma (OSCC), include all SCC of the alveolar 
ridge, retrimolar trigone, hard palate, floor of the mouth (FOM), buccal mucosa, gingiva, and 
tongue.  The highest incidence of OSCC occurs in the FOM, followed by the alveolar ridge, 
retrimolar trigone, buccal mucosa, hard palate, and tongue. Of these, OSCC of the tongue shows 
the most predilection for lymph node metastasis, followed by the alveolar ridge and retromolar 
trigone, FOM, buccal mucosa, and hard palate.   
The majority of oral cancer cases appear to occur in developing regions of the world, 
particularly in Central and South America, the Caribbean, Africa, Asia, and China (PISANI et al. 
1999). As is the situation in the United States, persons of lower socioeconomic status show the 
highest incidence of OSCC. In addition, studies have shown that males are two to three times 
more likely to develop OSCC (FRANCESCHI et al. 2000; REICHART 2001), and that African 
American males have a higher propensity for oral cancer than do their Caucasian counterparts 
(JEMAL et al. 2005).     
If identified early, the 5-year survival rates may be greater than 80%, however these rates 
decrease significantly for tumors identified at a later stage (FANG and FORASTIERE 2001).   
Unfortunately, more than 60% of patients diagnosed with OSCC are already at an advanced 
stage of the disease (KOWALSKI and SAN 1994; REPORT 2003).  Due to the late stage at diagnosis 
of most patients, the overall survival rate is less than 50%, which remains one of the lowest of all 
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 cancer types  (FANG and FORASTIERE 2001; REPORT 2003).  Therefore, it critical to devise more 
effective methods for improving the early detection of OSCC. 
 
2.2. ETIOLOGY OF ORAL SQUAMOUS CELL CARCINOMA 
 
To identify more effective biomarkers for the early detection of OSCC, it is important to 
understand the cellular processes and mechanisms by which normal oral mucosal cells become 
neoplastic.  Both SCCHN and its subset, OSCC, arise through an accumulation of genetic 
alterations including chromosomal alterations, DNA changes (eg., mutations, amplifications or 
deletions), and/or epigenetic alterations, such as changes in DNA methylation that affect genetic 
regulation.  These events are further influenced by exposure to environmental agents, including 
tobacco smoke, smokeless tobacco, alcoholic beverages, and/or viruses, such as human 
papillomavirus (FORASTIERE et al. 2001; HO and CALIFANO 2004; MORK et al. 2001). 
 
2.2.1. Tobacco 
 
The most prevalent risk factor for the majority of epithelial cancers is cigarette smoking.  
According to a study in the British Medical Bulletin, the global estimate for the number of 
individuals who smoke is greater than one billion (PETO et al. 1996).  The International Agency 
for Research on Cancer reports that the carcinogenic effects of smoking have been found in 
major organs including: bone marrow, bladder, cervix, kidney, liver, lung, pancreas, stomach, 
ureter, and all areas of the oral cavity, nasal cavity, nasal sinuses, larynx, and esophagus 
(INTERNATIONAL AGENCY FOR RESEARCH ON CANCER 2004).  Of particular note is that 95% of 
tumors arising within the oral cavity are attributed to smoking (REICHART 2001).  Normal cells 
are influenced by cigarette smoke through various biological mechanisms, including the 
formation of DNA adducts, single- and double-strand DNA breakage, inefficient DNA repair, 
chromosome segregation defects, and the inability of cell cycle checkpoints to identify, arrest, 
repair, or target affected cells for apoptosis (BENDER et al. 1988; GU et al. 1992; HSU et al. 1991; 
NAKAYAMA et al. 1985).  In vitro and in vivo cytogenetic effects of cigarette smoke condensate 
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 (CSC) include the formation of micronuclei (BALANSKY et al. 1987; BALANSKY et al. 1988; 
MOHTASHAMIPUR et al. 1987; MOHTASHAMIPUR et al. 1988; SAUNDERS et al. 2000; STOICHEV et 
al. 1993), lagging chromosomes (SABHARWAL et al. 1975; SAUNDERS et al. 2000), as well as 
chromosomal aneuploidy and various structural chromosome rearrangements (LAFI and PARRY 
1988; LUO et al. 2004).  Micronuclei have also been observed in the oral mucosa of smokeless 
tobacco users (KAYAL et al. 1993; LIVINGSTON et al. 1990; STICH et al. 1992).  In addition, sister 
chromatid exchanges (SCEs) are suggested to result from exposure to the alkylphenols and 
benzaldehydes in CSC (CURVALL et al. 1985; JANSSON et al. 1986; JANSSON et al. 1988).  More 
recent studies have demonstrated that CSC induces anaphase bridges as well as DNA double-
strand breaks (DSB) in normal human fibroblasts and normal oral kaeratinocytes, suggesting a 
direct association between cigarette smoking and genomic aberrations in human cells (LUO et al. 
2004).  
 
2.2.2. Alcohol 
 
The World Cancer Report indicates that excessive alcohol consumption is causally 
associated cancers of the oral cavity and liver, and is also categorized as a risk factor for cancers 
of the breast and colon (REPORT 2003). Recent findings in chick embryos have suggested that 
alcohol exposure and increased expression of vascular endothelial growth factor (VEGF) in 
combination with induced angiogenesis may have an important role in cancer progression (GU et 
al. 2005). The carcinogenic effects of alcohol appear to be most potent in cancers of the head and 
neck, in which heavy drinkers are 5 to10 times more likely to be affected than nondrinkers 
(REPORT 2003). Although ethanol by itself has not been proven to be carcinogenic, it is 
suggested that ethanol may act as a solvent, promoting absorption of other carcinogens, such as 
those in tobacco smoke, into target organs (BLOT 1992).  Alcohol has also been characterized as 
an enhancer of oxidizing agents within cells, which may lead to DNA damage, resulting in 
malignancy (SHAW et al. 1983). An alternative hypothesis suggests that genetic polymorphisms 
in alcohol metabolizing enzymes may result in various quantities of carcinogenic acetaldehyde 
(the primary metabolite of ethanol) within individuals consuming the same amount of alcohol 
(REPORT 2003). Interestingly, one study comparing dark colored spirits (such as Scotch whisky, 
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 Cognac, brandy, and dark rum) to lighter colored spirits (such as gin and vodka) suggested that 
consumption of darker alcoholic beverages appears to carry a higher risk for hypopharyngeal 
cancer (ROTHMAN et al. 1989). In addition, an association between poor diet and increased 
alcohol uptake has been suggested as another risk factor for cancer development (BLOT 1992). 
When combined with cigarette smoking, the risk for OSCC increases profoundly.  Studies have 
shown that while cigarette smoking alone may increase an individual’s risk two to four-fold, 
heavy drinking individuals who also smoke elevate their risk for OSCC six to 15-fold (MAIER et 
al. 1992; MORSE et al. 1996; ZAVRAS et al. 2001) 
 
2.2.3. Human papillomavirus (HPV) 
 
A significant proportion of SCCHN (20-25% of oropharyngeal and 20-50% of tonsillar 
SCC) are associated with HPV (GILLISON et al. 2000; HA and CALIFANO 2004; MORK et al. 
2001). Furthermore, HPV-positive individuals have a fifteen-fold increased risk of developing 
these cancers (MORK et al. 2001). However, this has not been proven in other subsets of SCCHN 
(GILLISON et al. 2000).  In an OSCC cell line, we demonstrated integration of human 
papillomavirus (HPV) within three chromosomal fragile sites (CFS), including the recently 
cloned FRA9E (CALLAHAN et al. 2003), suggesting that there may be an association between 
breakage at CFS and chromosomal instability in OSCC (RAGIN et al. 2004). The mechanism by 
which genetic instability is promoted through HPV infection relies on expression of viral 
oncogenes, E6 and E7 (HA and CALIFANO 2004). While E6 expression may result in failed 
cytokinesis, E7 expression may promote uncoupling of the centrosome duplication cycle with the 
cell division cycle (DUENSING and MUNGER 2001).  Despite distinct pathways, both mechanisms 
are associated with lagging chromosomes as well as anaphase bridges that result from 
chromosome breaks and rearrangements.  Therefore, E6 and E7 may not be mutually exclusive 
in cancer cells, and may act in combination to drive the phenotype of CIN. 
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2.3. GENETIC INSTABILITY 
 
An understanding of the neoplastic process requires discussion of multiple mechanisms 
involved in promoting changes within a cell that lead to inefficient repair of DNA damage and 
unregulated proliferation of the damaged cells. The overall term used to describe cumulative 
abnormalities present within a tumor is genomic instability.  Genomic instability results from the 
processes by which a somatic cell may become transformed through intrinsic DNA alterations, 
epigenetic changes, structural chromosomal aberrations, and numerical chromosomal changes. 
Despite the ongoing debate regarding how cells progress to malignancy, there is a general 
consensus that aside from normal mutation rates and possible clonal expansion of these 
mutations, three main sources of error can affect genomic stability in human cancers:  
nucleotide-excision repair instability (NER), microsatellite instability (MIN), and CIN. Loeb and 
colleagues refer to these terms collectively as a “mutator phenotype,” in which a mutation in any 
of the genes responsible for maintaining DNA fidelity through replication, repair, chromosome 
segregation, damage surveillance, or apoptosis may be responsible for human tumor formation 
and progression (LOEB et al. 2003).  While NER and MIN are usually characteristic defects in 
rare or hereditary cancers containing mutations in DNA mismatch repair genes, CIN is prevalent 
in cancers that do not contain nucleotide or microsatellite instability (LENGAUER et al. 1998).   
 
2.3.1. Nucleotide Excision Repair (NER) 
 
Nucleotide excision repair refers to the process of removing covalent alterations of DNA 
bases formed by exposure to environmental agents such as chemicals, ultraviolet light, or 
ionizing radiation (LENGAUER et al. 1998; SANCAR et al. 2004).  Six factors are involved in NER 
in humans.  DNA damage is recognized by three proteins: XPA, RPA, and XPC-TFIIH.  Their 
primary function is to recognize the site of damage by binding randomly to DNA.   The XPG 
factor makes a 3’ incision by replacing XPC at the damage site, followed by 5’ incision by XPF-
ERCC1, resulting in the release of the damaged DNA (reviewed in (SANCAR et al. 2004)).   
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 Individuals unable to properly repair mutations through NER have a higher susceptibility 
to cancer.  Deficiencies in NER are manifested through diseases such as ataxia telangiectasia 
(AT), Bloom syndrome, Cockayne syndrome, and xeroderma pigmentosum (XP).  In addition, 
this DNA damage pathway is particularly important for eliminating DNA adducts formed by 
exposure to tobacco smoke and ultraviolet radiation.  The majority of genes involved in the NER 
pathway appear to be polymorphic and have been studied in an effort to identify an association 
between genetic polymorphisms and cancer risk in smokers, including SCC. However, none of 
the polymorphisms observed in individuals at high-risk for developing cancer have shown an 
odds ratio greater than 2.1 (WU et al. 2004).  Therefore, the role of NER polymorphisms in 
tobacco-related cancers remains to be elucidated.   
 
2.3.2. Microsatellite Instability (MIN) 
 
Similar to NER, microsatellite instability results from defective DNA repair.  MIN is 
suggested to result from genetic mutations within a small number of genes (LENGAUER et al. 
1997b) in which MIN is expressed as a result of unrepaired strand slippage during DNA 
replication.  Microsatellites consist of simple repeats that range from di- or tri-nucleotide repeats 
to five or six nucleotide repeats found throughout the human genome (ELLEGREN 2004).  In 
many epithelial cancers including OSCC, breast, endometrium, lung, prostate, and stomach, 
alterations in microsatellite repeats have been observed (IONOV et al. 1993; ISHWAD et al. 1995; 
THIBODEAU et al. 1993; WOOSTER et al. 1994).  Interestingly, tumor cells with microsatellite 
instability (MIN) have been shown to express diploid karyotypes without chromosomal 
instability (CIN) (LENGAUER et al. 1998).  
Studies of both sporadic and hereditary nonpolyposis colon cancer (HNPCC) suggest that 
many tumors contain defects in mismatch repair genes (Day et al. 1996; Lengauer et al. 1997b).  
To date, eight mismatch repair (MMR) genes have been identified in humans: MSH2, MSH3, 
MSH5, MSH6, MLH1, MLH3, PMS1, and PMS2 (MACDONALD et al. 2004).  Human tumors 
expressing MIN have been shown to have defects in all MMR genes, except MSH3 and MSH5.  
Normally, MIN is identified through the protein MSH2, and both MSH3 and MSH2 assist in 
controlling the specificity of MMR.  In order to repair the damaged DNA, a repair complex 
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 consisting of MLH1, PMS2, MLH1/ MSH3, or MLH1/PMS1 as well as other factors is activated 
(MACDONALD et al. 2004).  Studies of HNPCC, prostate tumors, and tumors of the small 
intestine expressing a high level of MIN have been shown to contain mutations in the MLH1 
and/or MSH2 genes (Chen et al. 2003; Day et al. 1996; Lengauer et al. 1997b; Planck et al. 
2003).   Reduced expression levels of MLH1 and MSH2 have been associated with fewer 
recurrences and relapses for individuals with bladder cancer.   In contrast, patients with tumor 
cells expressing normal protein levels of hRAD50 and hMuts carry a higher probability of 
relapse (CATTO et al. 2003).  A similar phenotype has been shown in colorectal cell lines and 
sporadic colorectal tumors that are hypermethylated for hMLH1 (ARNOLD et al. 2004; KOINUMA 
et al. 2004; KUISMANEN et al. 2000; WHEELER et al. 1999).  In addition, higher mutation rates 
are observed in tumors expressing mutations in MMR genes and may be the result of altered 
tumor suppressor gene function (NICOLAIDES et al. 1994). MIN and loss of expression of MLH1 
has also been observed in esophageal SCC, however the authors concluded that the MIN was due 
to random replication errors rather than MMR deficiency, since loss of heterozygosity for p53 
was detected in 90% of the tumors studied (HAYASHI et al. 2003). 
 
2.3.3. Chromosomal Instability 
 
CIN is a common feature of human tumors, including oral cancer.  Although the 
karyotype of a particular tumor may remain quite stable over time, CIN can lead to “variations 
on a theme” of a clonal cell population, often with each cell within a tumor expressing a different 
karyotype.  Thus, CIN appears to be an important acquired feature of tumor cells, since 
propagation of diverse cells may aid certain cell subpopulations in evading standard therapies.  
Although there are several sources of CIN, the most prominent causes appear to be defects in 
chromosomal segregation, telomere stability, cell cycle checkpoint regulation, and the repair of 
DNA damage.  Our understanding of the biological basis of chromosomal instability in cancer 
cells is increasing rapidly and we are finding that the seemingly unrelated origins of this 
phenomenon may be related through the complex network of cellular signaling pathways.   
For nearly a century, neoplastic cells have been studied to investigate the origin of 
chromosomal aneuploidy and karyotypic instability (BOVERI 1914; LOEB et al. 2003; RASNICK 
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 and DUESBERG 1999).  Numerous reports have demonstrated that while aneuploidy most 
frequently results from chromosomal segregation defects and aberrant centrosome numbers 
(PIHAN and DOXSEY 1999; SAUNDERS et al. 2000), structural chromosomal abnormalities mainly 
result from telomere loss, anaphase bridging, and defects in the DNA damage response (BASSING 
et al. 2003; CELESTE et al. 2003; GISSELSSON et al. 2002; GISSELSSON et al. 2000; SHUSTER et al. 
2000). Despite these observations, interactions between the biological and genetic events that 
induce “chromosomal chaos” in tumor cells remain unclear and the mechanism(s) by which 
factors individually and cooperatively promote the CIN phenomenon in cancer are only starting 
to become elucidated (Fig. 1).   
To date, more than 100 genes have been identified in yeast that are responsible for 
promoting, inducing, and propagating CIN through defects in the mitotic apparatus, cell cycle 
regulation, and mitotic checkpoint control (SPENCER et al. 1990). Alterations in the expression of 
genes affecting mitotic spindle formation, such as β-tubulin (HUFFAKER et al. 1988) or mutations 
in the adenomatous polyposis coli (APC) gene, have been shown to alter chromosome 
segregation and promote CIN (PIHAN and DOXSEY 1999). In human leukemias and lymphomas, 
overexpression of the microtubule-associated protein, stathmin/Op18, has also been implicated in 
causing CIN (NYLANDER et al. 1995).  We and others have demonstrated that gene amplification 
may contribute to CIN through recurrent BFB cycles in human tumors (CIULLO et al. 2002; 
HELLMAN et al. 2002; SHUSTER et al. 2000). Mitotic checkpoint control genes that identify and 
correct spindle assembly defects, DNA damage, and errors in DNA replication include the 
human homolog BUB1 gene, hBUB1, which appears to play a direct role in causing CIN when 
mutated in colorectal cancer cell lines (CAHILL et al. 1998). Although defects in genes that 
regulate the DNA damage response have been shown to occur in the presence of CIN, the 
underlying cause and effect relationships are not well understood (GOLLIN 2004; GOLLIN 2005).   
In addition, previous studies have determined that centrosome amplification is an early event in  
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Figure 1.   Origins of chromosomal instability1. 
tumor formation and CIN, although the link between the centrosome duplication cycle and the 
mitotic cycle has yet to be elucidated (BRINKLEY 2001; KRAMER et al. 2002). Despite the fact 
that the mechanism(s) responsible for alterations in centrosome number are not defined, 
centrosome status has become useful for monitoring neoplastic progression and for assessing 
patient prognosis for some tumor types (GISSELSSON et al. 2002; PIHAN et al. 1998).  Thus, 
investigating the underlying causes of CIN may not only enhance diagnostic or prognostic 
information, but may also facilitate the development and administration of more effective 
treatment regimens for a wide variety of cancers.   
The following sections review the general causes of chromosomal instability in human 
tumors.  Specifically, they address the state of our knowledge regarding CIN in oral cancer and 
discuss various mechanisms responsible for the heterogeneous karyotypes seen in cancer cells 
within a tumor. 
 
1 In: Reshmi SC and Gollin SM (2005).  J Dent Res 84(2): 107-17.  Reprinted with permission. 
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2.3.3.1. Factors Leading to CIN: Loss of Cell Cycle Control 
 
 
Alterations in genes governing cell cycle control provide a green light for continued 
proliferation of defective cells.  Lengauer and colleagues (1998) described four main types of 
genes which, when altered, promote tumor progression: oncogenes, tumor suppressor genes, 
DNA repair genes, and genes regulating programmed cell death (apoptosis).  Tumors displaying 
complex chromosomal aberrations often contain increased copy numbers of oncogenes known to 
promote cell differentiation and proliferation.  At the same time, these tumors are also 
accumulating deletions or loss of genes responsible for detecting DNA damage, halting cell cycle 
progression, and/or mediating DNA repair (tumor suppressor genes) in cells prior to replication 
and/or cell division (KNUUTILA et al. 1999). 
 
 
STRUCTURAL GENETIC ALTERATIONS 
 
 
 
Previous studies have demonstrated that karyotypes of SCCHN and OSCC consist of 
near-triploid chromosome numbers and contain various patterns of cytogenetic aberrations, 
including structural and numerical chromosome abnormalities (GOLLIN 2001; JIN et al. 2002). 
These include, but are not limited to: aneuploidy (gains or losses of whole chromosomes 
resulting in a chromosome number altered from that of diploid cells, but which may or may not 
affect ploidy (AKERVALL et al. 1998); translocations (balanced or unbalanced rearrangement of 
chromosome segments or entire chromosome arms); insertions (breaks either within a 
chromosome or between two chromosomes resulting in the direct addition of chromosomal 
material or alternatively, the addition of material in the opposite, inverted direction); deletions 
(loss of small or large DNA segments); and amplifications (multiple additional copies of a 
specific gene or chromosomal region in the form of extrachromosomal double minutes (dmin) or 
intrachromosomal hsrs). 
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ONCOGENES 
 
 
 
If unaltered, oncogenes (termed protooncogenes, or genes having the potential to be 
transformed into an oncogene as a result of mutation) refer to genes that direct cell growth 
through regulatory pathways.  Oncogenes considered to play a role in SCCHN include growth 
factor receptors, such as FGF3, EGFR and ERBB2; intracellular signal transducers, such as RAS 
family members, RAF1, and STAT3; transcription factors, such as MYC, FOS, JUN, MYB; cell 
cycle regulators such as cyclin D1 (CCND1), and genes controlling apoptosis, such as BCL2 and 
BAX (reviewed in (NAGPAL and DAS 2003).  Alterations in any oncogene through chromosomal 
translocation, gene amplification, or viral insertion may provide an "on" switch for tumor 
development and/or progression.  
 
TUMOR SUPPRESSOR GENES 
 
 
Tumor suppressor genes (TSG) are negative growth regulators involved in cellular 
trafficking, regulation of the DNA damage response, and/or apoptosis (WEINBERG 1991).  When 
tumor suppressor gene function or regulation is altered by mutation or hypermethylation (JAIN 
2003), the ability to halt the proliferation of damaged cells is lost, allowing unrepaired cells to 
continue through the cell cycle.  TSG including FHIT, RB1, TP53, and CDKN2A ( p16INK4A) 
have been shown to play key roles in SCCHN tumorigenesis (KOONTONGKAEW et al. 2000; 
NAKAHARA et al. 2000; VIRGILIO et al. 1996).  Specifically, loss of TP53 function has been 
shown to correlate with poor response to chemotherapeutic agents such as platinum drugs and 
fluorouracil, as well as with resistance to radiotherapy (HAMAKAWA et al. 1998; O'CONNOR et al. 
1993; TEMAM et al. 2000).  In addition, loss of 3p14 and/or 9p21 are considered to be early 
events in HNSCC, and along with TP53 alterations, have been useful markers for monitoring 
increased recurrence risk (BRENNAN et al. 1995; CALIFANO et al. 1996; GOLLIN 2001; ISHWAD et 
al. 1996; ROSIN et al. 2002). 
In the absence of a functional TP53 gene, cells may become aneuploid (HARVEY et al. 
1993). Studies of colorectal cancer cell lines with MIN have demonstrated that cells with TP53 
mutations do not exhibit CIN (BUNZ et al. 2002; ESHLEMAN et al. 1998; LENGAUER et al. 
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 1997b).  Therefore, it is plausible that while defects in cell cycle checkpoint genes such as TP53 
permit cells with CIN to continue through the cell cycle, mutations in genes affecting the mitotic 
apparatus are more likely to have a direct role in causing the observed CIN in various neoplastic 
tissues. 
 
EPIGENETIC MODIFICATIONS 
 
 
 
One of the most common, heritable mechanisms by which gene function can be altered 
without DNA sequence changes is the process of methylation.   The presence of too little or too 
much methylation may have consequences in tumor cells.  For example, undermethylated 
colorectal tumor cell lines (LENGAUER et al. 1997a), murine cells lacking DNA 
methyltransferase (Dnmt1) (CHEN et al. 1998; GAUDET et al. 2003) and methylation mutations in 
immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome (XU et al. 1999a) 
suggest that methylation defects contribute to genomic instability and CIN.  In addition, 
retroviral integration and subsequent hypomethylation may encourage proto-oncogene activation 
(JAENISCH et al. 1985).  However, while inhibitors of DNA methyltransferase have been shown 
to be effective in the treatment of some human cancers (KARPF and JONES 2002), they may 
actually cause an increased risk of genomic instability in others (GAUDET et al. 2003).   
Hypermethylation has been shown to affect the fragile histidine triad (FHIT) gene in 
tumors of the breast and lung by silencing regions that may be important for suppression of 
tumor growth and proliferation under normal conditions (YANG et al. 2002; ZOCHBAUER-
MULLER et al. 2001). Recent reports have also demonstrated hypermethylated regions in tumor 
suppressor genes, including CDKN2B (p15), CDKN2A (p16), and TP53 in oral cancer (YEH et al. 
2003) and hypomethylation of oncogenes in metastatic HNSCC (SMIRAGLIA et al. 2003).  
Investigators are finding increasing evidence that specific tumors carry signature methylation 
patterns (EADS et al. 2001; FENG et al. 2005; TSOU et al. 2002). Thus, various investigators have 
suggested that methylation patterns could be useful screening tools for identifying individuals 
who may be at an increased risk for cancer development (FEINBERG and TYCKO 2004; 
MOMPARLER 2003).   
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2.3.3.2. Factors Inducing CIN 
 
 
 
DEFECTS IN DNA DAMAGE RESPONSE PATHWAYS 
 
 
 
Recent studies have revealed that many cellular pathways appear to be interconnected 
and/or intertwined.  The task of determining which DNA repair genes are involved in tumor 
progression and chromosomal instability remains challenging.  This is partly due to the 
observation that the same gene may play a role in one or more DNA damage response pathways.  
In addition, if one repair pathway is unable to function, it has been demonstrated that another 
repair pathway may be activated in its place (CLINE and HANAWALT 2003).  Examination of 
faulty DNA double strand break (DSB) repair caused by exposure to DNA damaging agents 
suggests that neoplasms may arise through factors influencing the ability of a cell to respond to 
alterations in DNA sequence.  Such factors include gene mutation, chromosomal deletions or 
amplifications, and/or other chromosomal alterations. There are five major DNA repair 
pathways:  homologous recombinational repair (HRR), non-homologous end joining (NHEJ), 
nucleotide excision repair (NER), base excision repair (BER), and mismatch repair (MMR) 
(BERNSTEIN et al. 2002).  Each is comprised of proteins essential for detecting and repairing 
specific types of DNA damage, but may also promote apoptosis in irreparably damaged cells.  
For the purpose of discussing chromosomal instability in oral cancer, there are key 
regulators that sense and respond to DSB, including the ataxia telangiectasia mutated (ATM) and 
ataxia telangiectasia and Rad3-related (ATR) genes.  Both have overlapping as well as unique 
responses to DNA damage and phosphorylate more than 15 known substrates, including p53, 
BRCA1, and the CHK1 and CHK2 kinases (SHILOH 2003).  Several of these genes, including 
ATM, TP53, BRCA1, CHEK2, FANC, BLM, and MRE11A are involved in familial cancer 
syndromes and may influence CIN (BECKER-CATANIA and GATTI 2001; GOLLIN 2004; GOLLIN 
2005).  The majority of human tumors carry TP53 mutations or are deficient in genes that initiate 
or respond to p53 function (NIGRO et al. 1989).  The p53 protein plays a major role in directing 
proteins involved in homologous recombination DSB repair, including BRCA1 and BRCA2, as 
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 well as RAD52.  However, p53 may also negatively regulate proteins, including RAD51 
(BUCCHOP et al. 1997), such that upregulation of RAD51 in tumors allows for a selective growth 
advantage for tumor cells in the absence of functional p53 (HENNING and STURZBECHER 2003).   
Though not studied in the current investigation, ongoing research in our laboratory is 
pursuing the hypothesis that loss of distal 11q is a critical step for promoting subsequent events 
involved in OSCC progression.  Chromosomal breakage at or near band 11q13 has been shown 
to result in loss of the distal segment of chromosome 11 (JIN et al. 1998b). Within the 
chromosomal segment distal to 11q13 are genes required for proper response to DNA damage.  
These include: MRE11A (MRE11 meiotic recombination 11 homolog A) at 11q21, histone 
H2AFX (H2A histone family, member X) at 11q22.3, the ataxia-telangiactasia mutated (ATM) 
gene at 11q23.2-q23.3, and CHEK1 (CHK1 checkpoint homolog) at 11q24.  Since localization of 
these genes is within the distal region of chromosome 11, which is lost prior to 11q13 gene 
amplification in almost half of OSCC, haploinsufficiency for these genes may be responsible for 
some of the observed CIN in oral cancer cells (Gollin and colleagues, unpublished data).  
Although the exact relationship between loss of function of these genes and CIN is currently 
unclear, the presence of haploinsufficiency for at least one of the DNA damage response genes, 
H2AFX, has been associated with the CIN phenotype in mice (BASSING et al. 2003; CELESTE et 
al. 2003). Fernandez-Capetillo et al. (2002) demonstrated that, under conditions of increasing 
DNA damage, H2afx-/- mice with functional Chk2 within the G2-M checkpoint signaling 
complexes are able to activate DNA repair pathways that do not require H2afx.  In addition, the 
authors showed that H2AX status affects phosphorylation of the DSB signaling protein, Trp5sbp, 
which has been recognized to affect phophorylation of Brca1 which is required for both S-phase 
and G2-M checkpoints following IR-induction (XU et al. 2001).  Somatic MRE11A mutations in 
colorectal cancer cell lines indicate the potential of a causal association between these mutations 
and CIN, but this remains to be determined (WANG et al. 2004b).  In addition, mice with mutant 
alleles for Mre11a phenotypically express cell cycle defects and genomic instability through 
impaired ATM function, but only progress to malignancy when present in p53+/- mice 
(THEUNISSEN et al. 2003). The consequence of distal 11q loss in OSCC cells may be loss of 
multiple tumor suppressor genes, that when combined with subsequent 11q13 gene 
amplification, results in an aggressive malignant phenotype (JIN et al. 1998b).  
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CHROMOSOMAL ANEUPLOIDY 
 
 
 
The term aneuploidy refers to the condition in which the chromosome number of the cells 
of an individual is not an exact multiple of the typical haploid set for that species  (KING and 
STANSFIELD 2002).  The presence of chromosomal aneuploidy in both early stage carcinomas 
and malignant neoplasms in general suggests its involvement, either directly or indirectly, in 
tumor progression (MITELMAN et al. 2004).   
Inactivation of several chromosomal segregation-related genes in normal human 
fibroblasts has been shown to influence early chromosome changes in preneoplastic cells. For 
example, haploinsufficiency for the spindle assembly checkpoint gene, MAD2, results in elevated 
frequencies of CIN in human cancer cells and murine primary embryonic fibroblasts (MICHEL et 
al. 2004).  Contrary to other inactivated checkpoint genes, only defects in BUB1 provided cells 
with the ability evade apoptosis (MUSIO et al. 2003).  Taken together, these studies suggest that 
the state of aneuploidy and/or chromosomal instability may be due to inefficient functioning of 
mitotic checkpoints, which may result in neoplastic progression.   
Sporadic missegregation, polyploidization, and/or defects in the mitotic apparatus may 
also promote aneuploidy.  Aborted mitosis (restitution) may result in failed formation of the 
cleavage furrow, leading to numerical doublings of chromosomes and centrosomes, termed 
tetraploidization (NIGG 2002).  This has been observed in a variety of cancers and may give rise 
to chromosomal aneuploidy through subsequent chromosome loss (GALIPEAU et al. 1996; 
SHACKNEY et al. 1995; SOUTHERN et al. 1997).    Oksala and Therman (1974) described the 
occurrence of tetraploidization particularly through disrupted cell division. In addition to mitotic 
arrest, a tetraploid chromosome number may result from failure of mitotic spindle formation 
(endomitosis), in which cells fall short of undergoing cytokinesis, resulting in a cell containing 
double the chromosome complement.  Tetraploidization may also occur through C-mitosis 
(spindle arrest in which chromosomes fail to align, resulting in the formation of several 
micronuclei comprised of the equivalent number of chromosomes in a tetraploid nucleus) or 
endoreduplication (chromosome replication carried out two times without an interruption by 
mitosis).  Still other cells may undergo amitosis (fusion of two nuclei from different stages of the 
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 cell cycle) or tripolar mitoses, the latter of which can result in three daughter cells, two of which 
may have near-triploid karyotypes and one with a near-diploid karyotype, all exhibiting 
chromosomal aneuploidy and CIN. 
The status of chromosomal ploidy in leukoplakia appears to be an important prognostic 
marker for oral carcinoma development and progression.  Sudbø et al. (2004) carried out a 
retrospective study designed to assess cancer development in 150 patients with dysplastic oral 
leukoplakia. The data revealed that of the patients identified with aneuploid epithelial dysplasia, 
96% (26/27) developed cancer compared to slightly fewer (80% or 16/20) of those with 
tetraploid lesions and only 5% (5/103) having diploid lesions.  Forty-five of 47 (96%) patients 
had negative resection margins and postoperative radiotherapy.  Of the five patients with a 
normal diploid chromosomal content, none developed a recurrence following tumor resection.  
However, more striking were the comparisons between patients with tetraploid lesions versus 
aneuploid lesions.  The study revealed that 25% (4/16) of patients with tetraploid status 
developed a recurrence, but survived.  This is in sharp contrast to the 26 patients with primary 
cancers due to aneuploid leukoplakia, in which 85% (22/26) showed evidence of recurrence and 
only one survived. Thus, there appears to be evidence suggesting that aneuploidy in the target 
tissue may be useful for predicting cancer development and recurrence, but has not yet proven to 
be useful for assessing response to intervention in OSCC. 
 
 
MITOTIC APPARATUS DEFECTS 
 
 
Karyotypic heterogeneity visualized by interphase cytogenetic analysis suggests that 
cytoskeletal defects may promote both clonal and nonclonal structural rearrangements in solid 
tumors, resulting in daughter cells that do not resemble each other or their mother cell (reviewed 
in (PIHAN and DOXSEY 1999; RESHMI et al. 2004).  The mitotic machinery is comprised of 
microtubules, centrosomes, kinetochores, and molecular motors. Properly choreographed 
coordination of these structures is essential for accurate chromosome segregation during mitosis.  
Defective functioning of the mitotic apparatus may continuously influence differences in both 
chromosome number and structure through subsequent cell divisions. 
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 Microtubules 
 
Microtubules provide ‘tracks’ for chromosome movement and the microtubule motors 
carry the chromosome cargo along the tracks (PIHAN and DOXSEY 1999). Alterations in 
microtubules directly resulting in chromosomal aneuploidy have not been demonstrated.  
However, a study by Lingle et al. (1998) showed that in breast tumors, increased levels of the 
centrosomal proteins, centrin and γ-tubulin, corresponded with significantly larger sized 
centrosomes. 
 
Centrosomes 
 
 
David Hansemann (1890) was first to report the presence of abnormal mitoses in cancer 
cells. His findings provided the groundwork for Theodor Boveri’s hypothesis that abnormal 
centrosome numbers influence chromosome segregation in cancer cells (BOVERI 1914).  
Subsequent studies have determined that centrosome amplification is indeed an early event in 
tumor formation (BRINKLEY 2001; LINGLE et al. 2002) and has been observed in cancers of the 
brain, bile duct, breast, colon, head and neck, lung, pancreas, and prostate and in human 
papillomavirus (HPV 16/18)- infected cervical cancers (NIGG 2002).  Various proteins that 
associate with centrosomes have been shown to influence centrosome duplication in human 
cancer.  Pericentrin levels were found to be elevated in breast and pancreas tumors (LINGLE et al. 
2002; PIHAN et al. 1998; PIHAN et al. 2001; SATO et al. 2001; ZHOU et al. 1998).  
Overexpression of cyclin E is associated with centrosome hyperamplification in both cultured 
cells and p53 null, heterozygous, and wild-type mice (MUSSMAN et al. 2000). CIN has also 
resulted from alterations of the centrosomal protein, γ-tubulin, which may be driven by 
overexpression of DNA polymerase β (BERGOGLIO et al. 2002).  
Overexpression of STK15/BTAK/aurora-A kinase in human pancreatic cancers (LI et al. 
2003) and ovarian cancers (GRITSKO et al. 2003) also results in centrosome amplification.  
Katayama et al. (2004) recently demonstrated a role for aurora kinase A in p53 phosphorylation, 
subsequently leading to increased Mdm2 binding.  Properly functioning Mdm2 targets p53 for 
ubiquitination and degradation.  Thus, the presence of increased levels of aurora-A kinase 
protein combined with increased Mdm2 expression results in cells with abnormal centrosomes 
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 and aberrant chromosome numbers to continue through the cell cycle by inactivating p53. Of 
particular interest in this study was the finding that MCF7 breast cancer cells overexpressing 
aurora-A kinase exposed to the DNA-damaging agent, cisplatin, were resistant to apoptosis.  
Thus, developing therapeutic agents targeting centrosomal proteins including aurora-A kinase 
are on the horizon (HARRINGTON et al. 2004).  
Other genes that may influence centrosome amplification are key regulators of the DNA 
damage response pathway and include ATR (FUCHS and CLEVELAND 1998), BRCA1 (SCHLIWA et 
al. 1999), BRCA2 (PIEL et al. 2001), and XRCC2/3 (GRIFFIN et al. 2000).  Proper functioning of 
the CHEK2 DNA damage kinase is required for influencing centrosomes in the absence of 
CHEK1.  The effect of losing the CHEK2 kinase appears to be epistatic, resulting in failed 
cytokinesis, increased centrosome number, and multipolar spindles (reviewed in Saunders, 
2005).   In addition, several genes necessary for protein degradation and mitosis have been 
shown to contribute to CIN by influencing centrosome numbers (reviewed in Nigg, 2002). 
Transactivation of TP53, BRCA2, and GADD45A (growth arrest and DNA-damage-inducible, 
alpha) by BRCA1 has been implicated in centrosome amplification (reviewed in Deng, 2002).  It 
has recently been shown that NEK2 (never in mitosis gene a-related kinase) is critical for proper 
formation of bipolar spindles (FARAGHER and FRY 2003).  NEK2 appears to have an inverse 
relationship with BRCA1. Overexpression of NIMA-related kinase 2 in Brca1-specific small 
interfering RNA treated, wild-type and Gadd45a- null mouse cells blocks hyperamplification of 
centrosome (WANG et al. 2004a).  Similar results have been observed between the interaction of 
BRCA1 with RB1 or CDK2 which may also give rise to cells without centrosome duplication 
(reviewed in Deng, 2002). These findings suggest that associations of BRCA1 with RB1 or 
CDK2 as well as proper functioning NEK2 play essential roles in maintaining genome stability. 
Although defective genes within the DNA damage response pathway have individually been 
shown to affect chromosomal instability through improper DNA double strand break repair, the 
exact mechanism by which they act in centrosome amplification remains to be defined (GOLLIN 
2004; GOLLIN 2005).  However, centrosome amplification has enabled monitoring of neoplastic 
progression, and has been shown to aid in the prognostic assessment of certain tumor types (KUO 
et al. 2000; PIHAN et al. 2001), including those of the head and neck (GISSELSSON et al. 2002; 
GUSTAFSON et al. 2000).  
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 Despite ongoing clinical trials in gene therapy, immunotherapy, and molecular-based 
agents for treatment of SCCHN, the heterogeneous nature of the cell populations within these 
tumors challenges the success of therapies targeted at specific genes.  Due to the recently 
identified connection between the DNA damage checkpoints and the DNA damage response 
pathway, additional therapies targeting checkpoint kinases such as CHEK1 and CHEK2, may 
chemosensitize cancer cells defective in the G2/M checkpoint and improve the overall prognosis 
for oral cancer patients (ZHOU and SAUSVILLE 2003).  Other cancer therapies focusing on the 
mitotic apparatus have proven to be effective for some cancers (ECKHARDT 2002; WALCZAK and 
CARDUCCI 2002).  For example, microtubule inhibitors, such as Taxol  (paclitaxel), Taxotere 
(docetaxel), and Vinca alkaloids (Vindesine, Vinorelbine), promote mitotic arrest and induce 
apoptosis and are used to treat solid tumors of the breast, esophagus, prostate, and lung 
(MOLLINEDO and GAJATE 2003; WALCZAK and CARDUCCI 2002).  Moreover, drugs such as VX-
680 that inhibit Aurora kinases and consequently suppress tumor growth in vivo are on the 
horizon (HARRINGTON et al. 2004). However, it has been suggested that in tumors with improper 
functioning checkpoints, these drugs may actually promote further CIN (DRAVIAM et al. 2004). 
This has been shown in colorectal cancer cell lines harboring mutations in checkpoint genes, in 
which cell lines expressing CIN were unaffected by anti-cancer agents such as nocodazole 
(CAHILL et al. 1998).  Thus, further insight into the mechanisms driving CIN will undoubtedly 
provide opportunities to identify new biomarkers to aid in diagnosis and prognosis, and achieve 
the ultimate goal of developing novel therapeutic strategies for patients with SCCHN. 
 
 
TELOMERE DYSFUNCTION 
 
 
Telomeres are small repetitive sequences located at the ends of chromosomes.  Their 
biological function is to protect chromosome ends from being “sticky” and from shortening at 
each DNA replication (BLACKBURN and CHALLONER 1984). When telomeres become too short, 
programmed cell death is initiated through activation of TP53-mediated apoptosis (CHIN et al. 
1999).  In the absence of a functional TP53 checkpoint, tumor cells with shortened telomeres 
may escape apoptosis.  The resulting “sticky,” uncapped chromosome ends are then free to 
associate with each other, causing end-to-end fusions which form dicentric chromosomes.  We 
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 and others have observed that migration of dicentric chromosomes during cell division may 
result in anaphase bridges (GISSELSSON et al. 2002; MCCLINTOCK 1938; MCCLINTOCK 1939). 
The pulling of two active centromeres to opposite poles creates an anaphase bridge, resulting in 
random, broken chromosome segments within each daughter cell.  The free, uncapped ends of 
these broken chromosomes are then capable of joining with other chromosomes lacking 
telomeres, giving rise to CIN.  If the new chromosome contains two active centromeres, 
anaphase bridge formation may again occur, promoting breakage-fusion-bridge (BFB) cycles 
(CHIN et al. 1999; MASER and DEPINHO 2002).  However, some cancer cells may activate the 
telomere maintenance enzyme, telomerase, which provides a selective growth advantage through 
telomere stabilization (MEYERSON 1998; VAZIRI and BENCHIMOL 1998).   Telomeres added to 
the ends of broken chromosomes resulting from BFB cycles may prevent chromosomes from 
further structural rearrangement and/or BFB cycles.  Studies of breast cancer, colorectal cancer, 
and leukemias have demonstrated that low levels of telomerase are present in preneoplastic cells 
compared to significantly higher levels in advanced stage tumors (reviewed in Maser and 
DePinho, 2002). In addition, telomerase status and expression of its subunits, particularly 
telomerase reverse transcriptase, hTERT, has proven to be a useful prognostic indicator in 
patients with OSCC.  Kannan et al. (1997) observed telomerase activity in normal, hyperplastic, 
well-differentiated, and moderately or poorly differentiated oral tumors and established a 
correlation between telomerase activity and OSCC tumor grade.  Later, Lee and colleagues 
(2001) demonstrated that 35 of 46 (76%) oral tumors showed hTERT expression and telomerase 
activity compared to no activity in the control specimens.  Due to the increased expression of 
telomerase in neoplastic cells, current research focusing on ways to reverse cellular immortality 
is actively being pursued.  Studies have shown that oral dysplastic cells treated with 5-aza-2-
deoxycytidine senesce resulting from the downregulation of telomerase (MCGREGOR et al. 
2002).  In addition, other therapies targeting telomerase have been suggested for a wide variety 
of tumor types (SHAY and RONINSON 2004). 
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2.3.3.3.  Factors Propagating CIN 
 
 
COMMON FRAGILE SITES (CFS) 
 
 
Chromosomal fragile sites (CFS) are sensitive regions of the genome which may form 
gaps or breaks in metaphase chromosomes when cells are grown under conditions that interfere 
with DNA replication and/or repair, including treatment with the DNA polymerase-α inhibitor, 
aphidicolin (ARLT et al. 2003). When treated with the G2M checkpoint inhibitor, caffeine, cells 
with unrepaired chromatin breaks enter mitosis and the incomplete repair may be visualized as 
breaks in chromosomes within metaphase cells (HECHT and GLOVER 1984). 
In contrast to rare fragile sites which are usually associated with specific disease 
phenotypes, there appears to be no underlying basis for the existence of common fragile sites 
within all individuals.  To date, nearly 90 common fragile sites have been identified 
(SUTHERLAND et al. 1998).  Although the current understanding of the structural makeup and 
function of chromosomal fragile sites remains largely unknown, fragile sites are thought to be 
the sites of stalled replication forks that result in DSB (CASPER et al. 2002).  Thus, a 
chromosomal rearrangement at a fragile site may be the result of an attempt to repair a cell 
exposed to DNA damaging agents such as cigarette smoke (GLOVER 1998; STEIN et al. 2002), 
caffeine, hypoxia, radiation, free radicals (RESHMI and GOLLIN 2005) and viruses such as HPV 
(RAGIN et al. 2004; THORLAND et al. 2003).  Based on what is currently known regarding CFS, 
many cover fairly large regions of DNA and contain areas of high flexibility (ARLT et al. 2003).  
However, despite differences in chromatin structure that confer a late replication pattern (LE 
BEAU et al. 1998), the increasing evidence that CFS are highly conserved between species 
suggests that key genes may be located within them (GLOVER et al. 1998; KRUMMEL et al. 2002; 
ROZIER et al. 2004; SHIRAISHI et al. 2001). 
 A role for fragile sites in cancer was proposed two decades ago (LEBEAU and ROWLEY 
1984; YUNIS and SORENG 1984).  Both suggested that various cancer breakpoints including those 
in leukemias, lymphomas, and solid tumors may correspond to chromosomal fragile sites.  Genes 
within this region may then be deleted, the function may be altered if translocated with another 
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 chromosome, or alternatlvely involved in gene amplification.  Several investigators have 
proposed that gene amplification may be the protective response of a cell to chromosomal 
breakage or DNA damage, treatment with cytotoxic drugs or to oxygen deprivation (CIULLO et 
al. 2002; COQUELLE et al. 1997; KUO et al. 1998; PIPIRAS et al. 1998; SINGER et al. 2000; STARK 
1993; TONNIES et al. 2003; WINDLE et al. 1991).  To date, nine common fragile sites, FRA3B, 
FRA4F, FRA6E, FRA7G, FRA7H, FRA8C, FRA9E, FRA16D, and FRAXB have been 
characterized and shown to exhibit genomic instability through loss of heterozygosity (LOH), 
loss of expression, viral integration, or promoting gene amplification in a variety of human 
tumors (ARLT et al. 2002; CAHILL et al. 1998; CALLAHAN et al. 2003; DENISON et al. 2003; 
HUANG et al. 1998; HUEBNER and CROCE 2001; KRUMMEL et al. 2000; MORELLI et al. 2002; 
ROZIER et al. 2004).  We previously reported LOH at 3p14.2 and aberrant transcript expression 
of FHIT in approximately one half of our OSCC cell lines (VIRGILIO et al. 1996). In addition, we 
demonstrated integration of human papillomavirus (HPV) within three CFS, including FRA9E, 
suggesting an association between breakage at a CFS and chromosomal instability in OSCC 
(RAGIN et al. 2004).   
Direct evidence has been found to link gene amplification with BFB events involving 
fragile sites in humans. Ciullo and colleagues (2002) demonstrated that breakage at FRA7I 
induced amplification of the prolactin inducible protein (PIP) gene, which is overexpressed in 
tumors of the prostate and metastatic breast cancer (AUTIERO et al. 1999; CLARK et al. 1999). 
They determined the physical map location for FRA7I, and carried out fluorescence in situ 
hybridization (FISH) using a T47D breast carcinoma cell line.  Dual-color FISH using a probe 
located proximally to FRA7I along with a probe for FRA7I revealed an inverted repeat pattern 
within T47D cells.  Confirmation of the BFB mechanism was carried out by additional FISH 
studies using a probe for the PIP gene along with a region telomeric to FRA7I, in order to 
demonstrate that sequences distal to the amplicon were not duplicated.   In vivo studies by 
Hellman et al. (2002) showed that amplification of the MET oncogene at FRA7G in gastric 
carcinomas resulted in clustering of recurrent breaks within the FRA7G site such that amplified 
segments displayed an inverted repeat pattern, as would be observed as a result of BFB cycles 
(HELLMAN et al. 2002; SHUSTER et al. 2000). Since subsequent breaks are considered to occur 
randomly as a result of anaphase bridging, BFB cycles may promote variations of amplicon 
length depending on the site of breakage (TOLEDO et al. 1992). Taken together, these 
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 investigations suggest that CFS breakage may enable subsequent amplification of genes that are 
not necessarily located within the fragile region, but proximal to it.  Intrachromosomal gene 
amplification through fusion of sister chromatids may ensue, leading to BFB cycles and further 
chromosomal instability.  
Four fragile sites have been identified in and around chromosomal band 11q13:  FRA11A 
at 11q13.3, FRA11B at 11q23.3, FRA11F at 11q14.2, and FRA11H at 11q13. Of these, increased 
breakage at FRA11A has been demonstrated in blood cells of smokers compared to nonsmokers 
(KAO-SHAN et al. 1987).  In addition, chromosome breakage at a CFS was observed in FRA11B, 
a rare folate-sensitive fragile site implicated in Jacobsen syndrome through breakage and 
subsequent chromosomal deletion of the proto-oncogene, CBL2 (JONES et al. 1994).  Typical 
features of this disorder include psychomotor delay, trigonocephaly, facial dysmorphism, cardiac 
defects, and thrombocytopenia, though none appear to occur consistently (PENNY et al. 1995).  
However, genotypic manifestations of rare fragile sites have typically been found to occur as 
trinucleotide expansion repeat disorders, rather than loss at a single locus (JONES et al. 2000).  
Both FRA11H and FRA11F are common fragile sites flanking the region harboring CCND1.  
Therefore, it is possible that amplification of CCND1 and other genes in band 11q13 may be due 
to their chromosomal location, since they appear to be surrounded by hotspots for chromosomal 
breakage.  Previous investigations from our laboratory have uncovered proximal and distal 
breakpoint regions relative to the commonly amplified 11q13 segment (HUANG et al. 2002).  
Taken together, these findings suggest that two breakage events, perhaps at fragile sites, may 
occur 1) between the RIN1 and CCND1 genes and 2) distal to the CCND1 gene, resulting in BFB 
cycles.   
 
GENE AMPLIFICATION 
 
 
Gene amplification is a common event in tumors and has been observed both in vivo and 
in vitro (STARK 1993; TLSTY et al. 1995).  Models for initiating gene amplification propose that 
this event may be the protective response of a cell to treatment with cytotoxic drugs (KUO et al. 
1998; SINGER et al. 2000; STARK 1993; TONNIES et al. 2003) or to oxygen deprivation 
(COQUELLE et al. 1998; RICE et al. 1986).  Current studies have demonstrated that gene 
amplification may be the result of breakage at common fragile sites (CIULLO et al. 2002; 
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 COQUELLE et al. 1997; PIPIRAS et al. 1998; STARK 1993; TONNIES et al. 2003). Collectively, 
these investigations propose that the initiating step for gene amplification is a double strand 
break.  
Two basic forms of gene amplification have been observed in mammalian cells.  Spriggs 
and colleagues (1962) first described the presence of dmin chromosomes in lung tumor cells. 
Dmin appear as extrachromosomal pairs of chromatin in metaphase cells, and have since been 
observed in a variety of human malignancies (SCHWAB 1999). A second form of gene 
amplification is present as a uniformly stained and expanded chromosomal band, termed an hsr.  
Hsrs were first described by Biedler and Spengler (1976) in metaphase cells from antifolate-
resistant Chinese hamster lung cultures.  The hsrs were later shown to correlate with resistance to 
methotrexate through increased levels of the enzyme, dihydrofolate reductase (MILBRANDT et al. 
1981). Hsrs are early replicating (HAMLIN and BIEDLER 1981; MILBRANDT et al. 1981), 
suggesting that genes residing within the amplified region (amplicon) may have essential roles in 
regulating cellular functions (HOLMQUIST 1992). Regardless of the form of amplification, 
overexpression of genes in dmin or hsrs has been associated with tumor progression (BOCKMUHL 
et al. 2002; COQUELLE et al. 1998; GOLLIN 2001; MICHALIDES et al. 1995).  In addition, the 
presence of gene amplification has proven to be a useful prognostic indicator for overall survival 
(AKERVALL et al. 1997; BRODEUR 2003; BRUCKERT et al. 2000; FIELD 1992) and response to 
therapy (PEGRAM et al. 2000). 
In OSCC, amplification of chromosomal band 11q13 occurs in the form of an hsr 
(BARTKOVA et al. 1995; LESE et al. 1995; MICHALIDES et al. 1995).  Amplification and 
overexpression of genes within 11q13 has been observed in approximately 45% of OSCC 
(AKERVALL et al. 1997; BARTKOVA et al. 1995; GOLLIN 2001; JIN et al. 1998b; LESE et al. 
1995), and in smaller percentages of other carcinomas such as those of the breast, bladder, liver, 
pancreas, ovary, and aerodigestive tract (SCHRAML et al. 1999). Genes contained in this region 
include cyclin D1 (CCND1), cortactin (EMS1), fibroblast growth factors 3, 4, and 19 (FGF3 and 
FGF4 also known as INT2 or HSTF1, respectively), fas associated via death domain (FADD), 
and tumor amplified and overexpressed sequence 1 and 2 (TAOS1and TAOS2)(BEKRI et al. 1997; 
HUANG et al. 2002; KATOH and KATOH 2003; SCHUURING et al. 1998).  In particular, CCND1 
gene function is critical for regulating cell division (JEANNON and WILSON 1998), and has been 
shown to play a key role in the pathogenesis of OSCC (AKERVALL et al. 1997; CHAMPEME et al. 
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 1995; MICHALIDES et al. 1995) as well as in local recurrence of breast cancer (CHAMPEME et al. 
1995).   
Previous investigations by our laboratory and others suggested a BFB cycle model for 
gene amplification (CIULLO et al. 2002; COQUELLE et al. 1997; MCCLINTOCK 1938; 
MCCLINTOCK 1939; SHUSTER et al. 2000), in which gene amplification occurs through anaphase 
bridges resulting from dicentric chromosomes formed by sister chromatid fusion of broken 
chromosome ends.  However, four other models for gene amplification have been observed in 
mammalian cells.  These include, 1) unequal sister chromatid exchange; 2) re-replication and 
integration; 3) episome-excision, and 4) conservative transposition.  The unequal sister 
chromatid exchange model is based on DNA damaging agents and/or chemicals in which cells 
overcome the insult through amplification of a protooncogene (PALL 1991).  This requires 
recombination of sequences flanking the amplified locus, in which the one cell receives two 
copies of the locus, and the other cell is then deficient for that locus.  The cell carrying the 
deletion would be unable to  compensate for the lost locus (HAMLIN et al. 1984).  In addition, 
gene amplification other models for gene amplification are not commonly assocaiated with an 
inverted duplication pattern of gene amplification.  The surviving amplified cell may then 
continue through subsequent cell cycles, which may result in further unequal sister chromatid 
exchanges and amplicons with varying length arranged in tandem2.  The overreplication and 
reintegration model suggests formation of: a) rereplicated DNA within loop structures that result 
in exrachromosomal DNA; b) sister chromatid breakage with varying degrees of fragmentation; 
c) inversion of the entire recombined sequence3, d) a dicentric chromosome and loss of material 
distal to the recombination site; e) endoreduplication or the entire chromosome or partial 
duplication of a chromosome (reviewed in (SCHIMKE et al. 1986)).  Both deletion/episome and 
conservative transposition models suggest a rolling circle replication intermediate (YOUNG and 
CULLUM 1987).   The rolling circle replication intermediate within these models suggests that a 
double-stranded break occurring prior to replication will repair itself by non-homologous 
recombination with either similar sequence ends or non-homologous ends. Recombination of the 
chromosome ends may initiate replication fork formation, in which a chromosome loop would 
form into a rolling circle.  The rolling circle would continue to promote replication within a 
 
2   Tandem duplication would resemble a sequence expressing: a-bcd-bcd-bcd-bcd-e. 
3   Suggests that an original sequence expressing –abcdefgh would be expressed as –hgfedcba within the 
    overreplicated sequence. 
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 single replication cycle until stalling of the replication fork occurs.  Replication fork stalling may 
then lead to another recombination event, which integrates the tandem sequence back into the 
chromosome and is observed as an hsr (reviewed in (HAMLIN et al. 1991; HASTINGS and 
ROSENBERG 2002; SCHIMKE 1984; STARK 1993; STARK and WAHL 1984; TRASK and HAMLIN 
1989; WINDLE and WAHL 1992).  If the sequence does not reintegrate, extrachromosomal dmin 
would then be expressed within the cell. The deletion/episome model suggests the amplified 
gene locus results from a chromosomal deletion in which the deleted sequence remains in the 
form of an episome.  The episome would then undergo rolling circle replication (WAHL 1989), 
and eventually manifest itself in the form of a dmin.  This model requires the episome to re-
integrate into its original locus in order to be observed as an hsr (TRASK and HAMLIN 1989).  
Lastly, the conservative transposition model for gene amplification suggests the presence of 
amplicon clusters on the same chromosome arm as the original locus, but distal to the original 
locus.  Our current study will investigate the primary mechanism by which 11q13 gene 
amplification occurs in OSCC cells.   
 
 
BREAKAGE-FUSION-BRIDGE (BFB) CYCLES 
 
 
 
One consequence of chromosomal breakage (and or telomere loss) is thought to involve 
fusion of sister chromatids following replication, giving rise to a dicentric chromosome.  At 
anaphase, the dicentric chromosome may be pulled to opposite poles, resulting in breakage, 
termed breakage-fusion-bridge cycles (MCCLINTOCK 1938; MCCLINTOCK 1939).  The formation 
of dicentric chromosomes (ARTANDI et al. 2000; RIBONI et al. 1997; SAWYER et al. 2000) and 
anaphase bridging (GISSELSSON et al. 2002; SAUNDERS et al. 2000) then results in CIN. We and 
others have shown that BFB cycles may lead to gene amplification (SHUSTER et al. 2000; SINGER 
et al. 2000) which most likely occurs through sister chromatid fusion (MA et al. 1993) leading to 
the formation of inverted duplications of the amplified segment in which the size of the amplicon  
determined by the site(s) of breakage (CIULLO et al. 2002; COQUELLE et al. 1997; TOLEDO et al. 
1992).  In addition, amplification due to BFB cycles may contain imperfect head-to-head 
symmetries as well as unequal distances between the amplicon and the telomere in clonal cell 
populations (TOLEDO et al. 1992).  We and others have also identified anaphase bridges and 
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 lagging chromosomes in OSCC cells (GISSELSSON et al. 2002; SAUNDERS et al. 2000).   These 
observations strongly suggest the presence of BFB cycles as one possible mechanism for 11q13 
amplification in OSCC. 
 
SUMMARY 
 
 
The major focus of the research presented herein addresses the question of how 
amplification of band 11q13 occurs and promotes CIN in OSCC.  To summarize our previous 
findings, we: 1) identified 11q13 gene amplification in the form of an hsr (LESE et al. 1995); 2) 
determined the presence of an inverted duplication pattern within the 11q13 amplicon (SHUSTER 
et al. 2000); and 3) physically mapped the 11q13 amplicon and demonstrated  breakpoint cluster 
regions flanking the amplified region (HUANG et al. 2002).  The current study investigates three 
patterns of CIN observed in OSCC: numerical chromosomal aberrations, structural chromosomal 
alterations, and gene amplification.  The following sections provide an overview of the rationale 
behind developing and testing our current hypothesis that 11q13 gene amplification in OSCC 
results from BFB cycles, and that breakage at a CFS may be the initial step in 11q13 gene 
amplification.  
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3. MATERIALS AND METHODS 
 
This investigation utilized twenty-eight human oral squamous cell carcinoma (OSCC) 
cell lines which were developed from outgrowths derived from primary tumors of consenting 
patients who were not previously treated with radiation therapy or chemotherapy (S.M. Gollin, 
J.K. Reddy, S. Comsa, K.M. Rossie, C.M. Lese, B.N. Appel, R. Wagner, E.N. Myers, and J.T. 
Johnson, unpublished, Table 1).  Peripheral blood samples were collected from anonymous, 
karyotypically normal, healthy male and female donors. 
 
3.1. CELL CULTURE 
 
3.1.1. OSCC cell lines 
 
All OSCC cell lines were obtained from cultures that were cryopreserved in the vapor phase 
of liquid nitrogen in 10% dimethyl sulfoxide (DMSO, Fisher Scientific, Pittsburgh, PA) in MEM 
medium (GIBCO-BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (Irvine 
Scientific, Santa Ana, CA) and gentamicin (Irvine Scientific) (M10 medium).  Each cell line was 
thawed using a 37°C waterbath followed by the addition of 1 mL of fresh M10 medium and 
centrifugation at 220 x g for 5 min.  The medium was aspirated and cells were resuspended in 5 
mL of fresh M10 medium.  Cells were transferred to a T25 flask and maintained at 37°C in a 
humidified incubator with 5% CO2 in air.  Once optimal growth was achieved, cells were 
subcultured into multiple flasks with appropriate corresponding passage numbers (Appendix A).  
Some of these cells were then studied and others cryopreserved for future studies. 
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Table 1.  Site of origin and features of patients from whom the OSCC cell lines were derived4. 
 
CELL LINE SITE GENDER AGE SMOKER 
UPCI:SCC003 Tonsil Female 65 Yes 
UPCI:SCC016 Tongue Female 81 No 
UPCI:SCC029B Buccal Mucosa Male 85 No 
UPCI:SCC032 RMT¶ Male 60 Yes 
UPCI:SCC036 Tonsil Male 56 Yes 
UPCI:SCC040 Tongue Male 51 No 
UPCI:SCC056 Tongue Male 76 Yes 
UPCI:SCC066 Mandible Female 75 Yes 
UPCI:SCC070 RMT Female 35 Yes 
UPCI:SCC075 Tongue Male 68 Yes 
UPCI:SCC077 FOM Male 57 Yes 
UPCI:SCC078 FOM Male 60 No 
UPCI:SCC084 RMT Male 53 Yes 
UPCI:SCC099 FOM Male 52 Yes 
UPCI:SCC103 Tongue Female 28 Yes 
UPCI:SCC104 FOM Male 58 Yes 
UPCI:SCC105 Alveolar Ridge Male 68 Yes 
UPCI:SCC111 FOM Female 69 Yes 
UPCI:SCC114 FOM Male 72 Yes 
UPCI:SCC116 Alveolar Ridge Male 58 No 
UPCI:SCC122 Alveolar Ridge Male 64 Yes 
UPCI:SCC125 Alveolar Ridge Female 78 Yes 
UPCI:SCC131 FOM Male 73 Yes 
UPCI:SCC136 RMT Female 64 Yes 
UPCI:SCC142 FOM Male 58 Yes 
UPCI:SCC154 Base of Tongue Male 53 Yes 
UPCI:SCC172 Mandible Male 69 Yes 
UPCI:SCC182 Tonsil Male 71 Yes 
 
 
4  RMT, Retrimolar Trigone; FOM, Floor of Mouth. 
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3.1.2. OSCC clones 
 
Clones from two OSCC cell lines (UPCI:SCC040 and UPCI:SCC131) were developed 
according to the procedure described by Lengauer et al. (1997b).  Briefly, single cell dilutions 
were carried out in one, 64-well plate for each cell line.  Individual cells from the two OSCC cell 
lines were observed in four wells each.  However, clones A and B from UPCI:SCC131 were lost 
due to contamination.   The remaining clones were transferred to T25 flasks and cultured as 
usual (section 3.1.1).   
To obtain sufficient cells for multiple experiments, two 75 mm2 flasks were harvested for 
each clone.  Briefly, cells were passaged approximately 12 times then grown to 70% confluency. 
To each flask, 0.1µg/ml Colcemid™ (Irvine Scientific) was added for 5 hr.  Cells were removed 
using trypsin/EDTA (Irvine Scientific) and centrifuged at 320 x g for 7 min.  Cell pellets were 
the subjected to a 0.075 M hypotonic KCl solution for 20 min at 37°C followed by the addition 
of 0.5 mL cold fixative solution (3:1 methanol:acetic acid) and centrifugation.  The supernatant 
was removed by aspiration.  Cells were resuspended and 7 ml of cold, fresh fixative was added 
to each pellet.  Cells were centrifuged at 320 x g for 15 min, and washed two more times with 
fresh cold fixative, then stored in pellet form at -20°C until use. 
 
 
3.1.3. Peripheral blood cells 
3.1.3.1. Controls 
 
Blood samples were obtained from anonymous, karyotypically normal, healthy male and 
female donors.  Blood samples were collected in green top blood collection vials containing 
sodium heparin in order to prevent blood clot formation.  Approximately 200 µl of blood was 
inoculated into 15 mL conical tubes containing 5 mL of PB Max™ (GIBCO) peripheral blood 
medium including 10% fetal bovine serum (FBS), gentamicin sulfate (35 mcg/mL), L-glutamine, 
and phytohemagglutinin and cultured for 72 hours at 37°C in a slant rack.  
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 Cells were harvested 72 h after culture initiation.  Briefly, 0.1 µg/ml Colcemid™ was 
added to each normal peripheral blood cell culture for 25 min (see Appendix B for detailed 
protocol).  Cells were then centrifuged at 320 x g for 7 min.  The supernatant was removed by 
aspiration and the cell pellets were resuspended by tapping.  Cell pellets were then subjected to a 
0.075 M hypotonic KCl solution for 15 min at 37°C followed by the addition of cold fixative 
solution (3:1 methanol:acetic acid), inverted, then centrifuged.  The supernatant was removed by 
aspiration and 7 ml of cold fixative was added to resuspend each pellet.  Cells were pelleted by 
centrifugation at 320 x g for 15 min, and washed multiple times until clean, opaque pellet was 
visualized.  All fixed cell pellets were stored at -20°C until use. 
 
 
3.1.3.2. Inducing common fragile site breakage in blood cells 
 
To induce chromosome breakage that reveals the presence of common fragile sites, 
peripheral blood cells were cultured in peripheral blood medium for 48 h.  Next, 0.4 µM 
aphidicolin was added to each culture for 21 h, followed by 6 h exposure to 5 mM caffeine and 
then a 3.5 h Colcemid™ arrest prior to harvest.  Cells were then harvested according to the 
procedure described previously (section 3.1.3.1).   
 
 
3.1.4. OSCC chamber slides 
 
Following recovery from cryopreservation, one flask at 50% confluency from each OSCC 
cell line was plated in a chamber slide.   To do this, the supernatant was removed from each 
flask.  Cells were rinsed with 1XHBSS (Irvine Scientific).  Cells were removed from flask using 
trypsin/EDTA (Irvine Scientific) followed by the addition of an equal volume of M10 medium 
with 10% FBS.  For each chamber slide, 0.5 mL of cells was transferred to each of three 
chamber slides per cell line.  Chamber slides were placed at 37°C in a humidified incubator with 
5% CO2 for one hour to promote adherence of cells to the slide and then flooded with 1.5 mL 
complete M10 medium.  OSCC cells were maintained until each chamber slide reached 70-80% 
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 confluence.  Media was then removed by aspiration, and 2 mL fresh M10 was added to each 
chamber slide.  Next, 5 µL of Colcemid™ was added to each chamber slide and the slides were 
placed at 37°C in a humidified incubator with 5% CO2 for 21 h to maximize the number of cells 
in metaphase.  Slides were then washed twice with M10 medium which was removed by 
aspiration.  To each chamber slide, 2 ml of fresh M10 was added for 2 h.  The M10 medium was 
then removed by aspiration and the cells on chamber slides were fixed in 3:1 methanol:acetic 
acid for 30 min, air dried, and stored with dessicant at -20°C until use. 
 
 
3.2. CLASSICAL CYTOGENETIC ANALYSIS OF OSCC CLONES 
 
Slides with cells from OSCC parental lines (UPCI:SCC131 and UPCI:SCC040) as well 
as daughter clones were trypsin-Giemsa banded using standard classical cytogenetic procedures 
(HEO et al. 1989). Briefly, slides were subjected to a 8.3% trypsin solution (Irvine Scientific, 
Santa Ana, CA) in 1XPBS followed by inactivation in 3.33% fetal bovine serum (Irvine 
Scientific) in 1XPBS, rinsed in 1XPBS, then stained with 6.7% Giemsa (Sigma) in Gurr’s buffer 
followed by removal of excess stain with Gurr’s buffer (Appendix C).  Five cells from each of 
two clones, UPCI:SCC040 and UPCI:SCC131, were analyzed.  Individual cells were captured 
digitally and karyotyped using the CytoVision Ultra System (Applied Imaging, Santa Clara, 
CA).  A composite karyotype was generated in accordance with the ISCN nomenclature (ISCN 
1995). 
 
3.3. SPECTRAL KARYOTYPE (SKY™) ANALYSIS OF OSCC CLONES 
 
In order to carry out 24-color FISH to further identify structural abnormalities observed 
in the G-banded karyotypes of the OSCC clones, fresh slides were prepared from each parental 
cell line and the respective daughter clones.  The SkyPaint kit (Applied Spectral Imaging, 
Carlsbad, CA) was used according to published methods (VELDMAN et al. 1997).  Ten metaphase 
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 cells were captured using the SkyVision I System (Applied Spectral Imaging). Five cells from 
each parental cell line and each clone were selected for analysis. 
 
3.4. PREPARATION OF DNA PROBES FOR FISH 
 
3.4.1. Preparation of alpha-satellite probes 
 
Alpha-satellite plasmids specific for chromosomes 4, 6, 7, 9, 17, 20, and X were provided 
by Dr. Mariano Rocchi of the University of Bari, Italy (http://www.biologia.uniba.it/rmc/).  All 
plasmids were plated onto LB agar supplemented with ampicillin (50 µg/ml) and placed in a 
warm room for 16 h to grow individual colonies.  Individual colonies were then picked and 
cultured in LB Broth supplemented with ampicillin (50µg/ml) and placed in a warm room for 16 
h to maximize growth.  Each culture was then extracted using the Qiagen midiprep kit procedure 
(Valencia, CA).  Following verification of DNA concentration on a 1% agarose gel, extractions 
were stored at -20ºC until use.   
Alpha-satellite plasmids specific for chromosomes 4, 6, 7, 9, 17, 20, and X were directly 
labeled with either Spectrum Green™-dUTP or Spectrum Orange™-dUTP as instructed by the 
Vysis nick translation kit protocol (Vysis, Downers Grove, IL)(see Appendix D).  A commercial, 
CEP 11 probe directly labeled with Spectrum Green™ (Vysis) was also used for these analyses.     
 
 
3.4.2. Preparation of BAC probes 
 
Human BAC clones were identified from the RP11 library and ordered from the 
BACPAC Resources website (http://www.chori.org/bacpac).  All clones used in the current study 
were obtained from Children’s Hospital Oakland Research Institute (CHORI, Oakland, CA).  
BACs were cultured in LB Broth supplemented with chloramphenicol (50µg/ml) and extracted 
using the standard laboratory protocol for phenol/chloroform extraction (Appendix D).  
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 For studying anaphase bridges in OSCC cell lines, human BAC clone (RP11-699M19) 
corresponding to the CCND1 locus was used along with a cosmid contig for RIN1.  The RIN1 
probe was a gift from Dr. John Colicelli of the University of California, Los Angeles and was 
originally obtained from a human glioblastoma cDNA library (COLICELLI et al. 1991).  The 5-kb 
cDNA probe corresponded to two cosmids (LA11NCO-9C6, LA11NC01-41C9) which were 
used in combination to cover the RIN1 region.  For FISH, the CCND1 BAC was labeled in 
Spectrum-Green™ (Vysis) and both cosmids spanning RIN1 were labeled in Spectrum-Orange™ 
as instructed by the Vysis nick translation kit protocol (Vysis). 
With the exception of the fluorescent tag, all other reagents were present in the Vysis 
nick translation kit (Vysis). A total of 1 µg of DNA was labeled in one of three fluorescent tags: 
Spectrum-Orange™ (Vysis), Spectrum-Green™ (Vysis), or diethylaminocoumarin-5-dUTP 213 
(DEAC213; PerkinElmer Life and Analytical Sciences, Inc., Boston, MA).  For each slide, 
approximately 10 µl of each labeled probe was precipitated using human Cot-1 DNA, nuclease- 
free water, placental DNA, sodium acetate, and 100% ethanol (see Appendix D for detailed 
procedure).  Probes were then dissolved in 7 µl hybridization buffer (50% 
formamide/2XSSC/10% dextran sulfate) and 3 µl water for a total of 10 µl per 22mm2 coverslip 
area.  Probes were agitated at 37°C for 30-60 min, pulse centrifuged in an Eppendorf centrifuge  
(Model 5415 D, Fisher Scientific) to ensure collection of the entire FISH probe, then denatured 
at 75°C for 5 min and pre-annealed at 37°C for 15-30 min.  
 
3.5. FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 
 
The general FISH procedure has been described elsewhere (LICHTER and RIED 1994).  
For the studies described, identical FISH procedures were carried out (for detailed procedure see 
Appendix E).  Briefly, all slides for FISH were pretreated with 100 µg/ml RNase (Sigma-Aldrich 
Corp., St. Louis, MO) in 2XSSC for 30-60 min at 37°C to remove excess cytoplasm.  Slides 
were then washed three times in 2XSSC at room temperature and dehydrated with a 70, 80, and 
100% ethanol series.  The slides were then denatured in a 70% formamide/2XSSC solution (pH 
7.0) at 75°C for 2 min, followed by another ethanol dehydration series.  Slides were placed on a 
55°C slide warmer while probe was applied, coverslipped, and sealed with rubber cement.  
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 Slides were incubated overnight in a 37°C humidified chamber.  To remove excess unhybridized 
probe, slides were washed in 0.4XSSC/0.3%NP-40 Tween 20 at 72°C followed by a 2 min wash 
with 2XSSC/0.1% Tween 20 at room temperature.  To visualize the DNA for analysis, slides 
were counterstained with 4’,6-Diamidino-2-phenylindole (DAPI, Sigma) and antifade solution 
(Fisher Scientific, Pittsburgh, PA) was applied prior to sealing with a glass coverslip.  All slides 
were analyzed using an Olympus BX61 fluorescence microscope.  Images were captured using 
CytoVision Ultra with version 3.5 Genus software (Applied Imaging, Santa Clara, CA).  
 
3.6. ANALYSIS OF FISH HYBRIDIZATIONS 
 
3.6.1. OSCC clone comparison 
 
Dual-color FISH with alpha-satellite probes was carried out on individual slides containing 
metaphase cells from the UPCI:SCC040 and UPCI:SCC131 parental cell lines and two daughter 
clones, each.   Following FISH (see Section 3.5), slides were stored at –20°C until viewing.  
Approximately 200 nuclei were evaluated for each alpha-satellite probe.  Analysis was carried 
out using an Olympus (New Hyde Park, NY) BHS fluorescence microscope and images were 
captured using the CytoVision Ultra (Applied Imaging, Santa Clara, CA).   
 
 
3.6.2. Analysis of anaphase bridges 
 
In order to identify and quantify the number of anaphase bridges expressing the inverted 
duplication pattern characteristic of the BFB model for gene amplification, we hybridized 
differentially labeled CCND1 and RIN1 probes to chamber slides from 29 OSCC cell lines.  Of 
these, four, SCC cell lines were obtained from Thomas Carey, Ph.D. (University of Michigan 
Cancer Center) for our investigation.  The RIN1 probe was directly labeled in Spectrum 
Orange™ (Vysis) and the RP11-699M19 CCND1 BAC was directly labeled in Spectrum 
Green™ (Vysis) and hybridized to cells on chamber slides (see Section 3.4.2). Approximately 40 
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 anaphase bridges were analyzed from each cell line for the presence of RIN1 and CCND1 FISH 
sequences.   
The amplification status of CCND1 was also determined by examining interphase nuclei on 
the same chamber slide.    We defined an OSCC cell line as amplified if at least 2% of interphase 
nuclei had >10 copies of the CCND1 gene.  In order to determine statistical significance, we used 
a t-test to compare the percentage of cells with amplification expressing the inverted duplication 
pattern of CCND1 and/or RIN1 in anaphase bridges versus those without amplification 
(Appendix I).  In addition, the Spearman correlation test was carried out to determine if 
differences were present between the percentage of amplified cells and the percentage of 
anaphase bridges containing the inverted duplication sequences.  
 
3.6.3.       Identification of FRA11F 
 
Previous studies by our laboratory identified two breakpoint cluster regions that flank 
the11q13 amplicon in our OSCC cell lines (Fig. 5, Huang et al., 2002). In order to determine the 
physical map location of FRA11F, BACs were selected from the RP11- library using the NCBI 
database as previously described (Section 3.4.2) and hybridized to cells treated to express 
common fragile sites (Section 3.1.3.2)(Table 2).   To be considered a region within a fragile site, 
an individual BAC must be observed as having three distinct patterns of hybridization: 1) 
binding only to the proximal side of the chromosome break; 2) binding to both sides of the 
chromosome break, crossing the fragile site; and 3) binding only to the distal side of the 
chromosome break. 
To localize FRA11F, BACs were labeled in Spectrum Orange™ or Spectrum Green™ as 
decribed (Section 3.4.2.) and hybridized in pairs to aphidicolin and caffeine (APCC) treated 
metaphase blood cells and cultured OSCC cells using the standard laboratory FISH protocol 
(Section 3.5). 
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Table 2.  BAC clones used to identify FRA11F in peripheral blood cells treated to induce  
               CFS with APCC. 
 
BAC NAME 
RP11-672A2 
RP11-483P13 
RP11-98G24 
RP11-O31F2 
RP11-79B7 
RP11-118L16 
RP11-89M14 
RP11-281H14 
RP11-613J18 
RP11-19P3 
RP11-131C11 
RP11-89H11 
RP11-141H6 
RP11-313I2 
RP11-30C9 
RP11-18G9 
RP11-325I16 
RP11-208P3 
RP11-841F15 
RP11-372E19 
 
 
 
3.6.4. Determination of FRA11F status in OSCC cells 
 
To test our hypothesis that breakage at a common fragile site may initiate 11q13 gene 
amplification, we carried out dual-color FISH using FRA11F BACs RP11- 208P3, 303I2, 
841F15, and 281H14 along with RP11-699M19 for CCND1 on OSCC cell lines.  For cell lines 
expressing complex hybridization patterns, we used three-color FISH for CCND1, proximal 
FRA11F, and distal FRA11F to further clarify the status of FRA11F.  BACs for proximal 
FRA11F (RP11- 281H14, 303I2) were labeled in Spectrum Green™, distal FRA11F (RP11- 
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 208P38) in Spectrum Orange™, and CCND1 (RP11-699M19) directly labeled in 
diethylaminocoumarin- 5-dUTP 213 (DEAC 213) for aqua.   
 
3.7. HELIX FLEXIBILITY ANALYSIS OF FRA11F 
 
Previous studies have demonstrated that CFS contain regions of high flexibility (MISHMAR et 
al. 1998; MORELLI et al. 2002), although the structural chromatin element conferring this 
fragility remains to be elucidated.  To determine the flexibility status of FRA11F, we used the 
FlexStab computer program downloaded from the Hebrew University of Jerusalem website, 
(http://leonardo.ls.huji.ac.il/departments/genesite/faculty/bkerem.htm), to analyze the 7.5 Mb 
sequence (see Appendix F for program).  The purpose of this program is to measure variation in 
the DNA structure which is expressed as TWIST angle fluctuations, defined as rotation of base 
pair relative to the perpendicular base plane (SARAI et al. 1989).  The program measures this by 
summing up dinucleotide values in a given window size, in which AT appears to express high 
fliexibility versus homonucleotide sequences (GG/CC and AA/TT).  Similar output is obtained 
when measuring helix stability, however the values are based on a helix-to-coil transition which 
is expressed in Kcal/mol. Stability is assessed as a function of base sequence and its neighbor 
bases in which interactions may be: AA/TT, AT/TA, TA/AT, CA/GT, GT/CA, CT/GA, GA/CT, 
CG/GC, GC/CG, GG/CC (BRESLAUER et al. 1986). Using these interactions, the authors 
demonstrated that calculating values in terms of base sequence versus base composition results 
in different thermodynamic profiles.    
Due to the extremely large size of the FRA11F sequence, it was divided into several 
segments of approximately 330 kb per run for flexibility analysis (Appendix G).  The mean and 
standard deviation values were then calculated for each sequence using a program designed by 
Dr. Xin Huang of our laboratory group at the University of Pittsburgh based on previously 
described methods (MISHMAR et al. 1998).  To determine the percentage of AT versus GC 
composition within the FRA11F sequence, we ran the FlexStab computer program again, 
substituting AT/GC content in the sequence file.  
 
 
 
 
40
 4.      RESULTS 
 
4.1. CIN IN OSCC CELLS 
 
Our current investigation focuses on determining the origins of CIN in OSCC cells.  
Three characteristic patterns of CIN include: numerical chromosomal aberrations, structural 
chromosomal alterations, and gene amplification.  The purpose of this study is to determine 
whether or not OSCC cells express heterogenous karyotypes despite a clonal background of 
chromosome aberrations. To investigate chromosomal instability in oral squamous cell 
carcinoma, two OSCC cell lines, UPCI:SCC040 and UPCI:SCC131, were cloned, harvested, and 
analyzed using FISH probes specific for the alpha-satellite region of eight different 
chromosomes.  Cells from both OSCC cell lines showed variations in the modal chromosome 
number between clones of each cell line (Table 3).  For example, clone A from UPCI:SCC040 
showed a modal number of two for chromosome 4, however clone B contained a modal number 
of four for the same chromosome (Fig. 2, top left).  Similarly, Clone B appeared to express a 
higher percentage of cells with an extra signal for the centromere of chromosome 9 compared to 
Clone A, whereas Clone A showed extra copies for the centromere of chromosome 7 in a higher 
percentage of cells than Clone B.  However, signals for all other centromere probes appeared to 
be stable between the SCC040 clones (Fig. 2, bottom left).  Comparison of clones from 
UPCI:SCC131 revealed similar variability to those of UPCI:SCC040.  Interestingly, the modal 
number of chromosomes appeared to be distinct for each clone for the centromere probes of 
chromosomes 4 (Fig. 2, top right) and 7 in clones C and D, respectively. Although the modal 
chromosome number varied between clones from each cell line, one or two chromosomes from 
the panel remained relatively constant. UPCI:SCC040 expressed four copies of chromosome 17 
and two copies of the X chromosome in each of the four clones, whereas UPCI:SCC131 had four 
copies of chromosome 20 (Fig. 2, bottom right) and two copies of the X chromosome in both 
clones.  Among the chromosomes studied, chromosomes 4 and 9 appeared to vary the most 
between clones of each cell line. 
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 Table 3.  Chromosome instability in cloned UPCI: oral squamous cell carcinoma cell  
               lines5. 
 
 
UPCI:Cell Line 
 
 
Chrom6  
4 
 
 
Chrom 
6 
 
Chrom 
7 
 
Chrom 
9 
 
Chrom 
11 
 
Chrom
17 
 
Chrom 
20 
 
Chrom 
X 
 
Average
SCC040 
Clone A 
2 
40% 
4 
23% 
5 
27% 
4 
24% 
4 
5% 
4 
11% 
4 
22% 
2 
9% 
3.6 
20% 
SCC040 
Clone B 
4 
15% 
 ND7
ND 
4 
9% 
5 
22% 
4 
10% 
4 
4% 
4 
9% 
2 
4% 
3.9 
10% 
SCC131 
Clone C 
2c 
10% 
ND 
ND 
4 
40% 
6 
39% 
3/5 
26% 
3 
26% 
4†
16% 
2 
14% 
3.6 
21% 
SCC131 
Clone D 
3 
12% 
ND 
ND 
4 
13% 
7 
46% 
3 
9% 
4 
18% 
4 
13% 
2 
4% 
3.9 
16% 
Normal 
Lymphocytes 
2 
0% 
2 
5% 
2 
0% 
2 
1% 
2 
2% 
2 
3% 
2 
0% 
2 
5% 
2 
2% 
 
Of particular interest were metaphase cells observed during the FISH analysis of each 
clone.  Despite similar modal chromosome numbers obtained by interphase and metaphase FISH 
analyses, we found that the chromosome copy number did not necessarily represent the same 
chromosome in each cell analyzed.  For example, UPCI:SCC131 Clone D showed the presence 
of three copies of chromosome 17 and four copies of chromosome 11.  Although the findings for 
chromosome 17 remained the same (two normal chromosome 17s and one derivative 
chromosome 17), the chromosome 11 copy number signals represented two normal 
chromosomes 11 and two derivative chromosomes 11 with a homogeneously staining region 
(hsr) at band 11q13 in one cell (Fig. 3A, left).  Another cell expressed two normal 11s, one 
derivative 11 with the same hsr, and one dicentric, translocated chromosome 11 with the hsr 
(Fig. 3A, right). 
To characterize the variation in chromosome number and structure between individual 
cells within a clone compared to other clones and the parental cell lines, G-banding and SKY 
were carried out.  Approximately five cells from each parental cell line and two daughter clones 
 
5  In: Reshmi et al. (2003). Genes Chromosomes Cancer 41:38-46.  Reprinted with permission.   
    For each chromosome tested, the modal chromosome number was determined, and the percentage of cells that  
    differed from the modal number is shown. 
6  Chromosome number. 
7  ND, not determined. 
†  Different cell passage used for analysis. 
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 each were examined by both methods.  All cell lines expressed gains, losses, and clonal 
structural abnormalities.  However, despite a common background of abnormalities, no two cells 
were alike within a cell line or between the cell line clones (Fig. 4).   
 
 
 
 
Figure 2.   Alpha-satellite FISH results showing chromosomal variation between clones.8   
 
8  In: Reshmi et al. (2003). Genes Chromosomes Cancer 41:38-46.  Reprinted with permission. 
    UPCI:SCC040 Clones A and B (top, left) and UPCI:SCC131 Clones C and D (top, right) results for the  
    centromere of chromosome 4; Chromosomal similarities from UPCI:SCC040 Clones A and B (bottom, left) for  
    the centromere of chromosome 17; Chromosomal similarities from UPCI:SCC Clones C and D (bottom, right) for  
    the centromere of chromosome 20.  The X-axis represents the number of alpha-satellite signals present; the Y-   
    axis represents the percentage of cells expressing each signal. 
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Figure 3.   FISH and SKY marker chromosome evolution in OSCC cells9. 
A) Metaphase fluorescence in situ hybridization images from UPCI:SCC131 Clone D using centromere 
probes 11 (green, arrowheads) and 17 (orange, arrows).  Note that the four copies of chromosome 11 
represent structurally different chromosomes in each cell; B) Marker chromosome evolution in  
UPCI:SCC131.  Note that markers contain material of similar chromosomal origin, however vary in 
segment size; C) Marker chromosome evolution in UPCI:SCC040. Note the novel translocations from 
segments of the parental cell line (far left) that have combined with broken chromosome segments of 
other chromosomes (Clones A and B, respectively). 
 
 
 
9  In: Reshmi et al. (2003). Genes Chromosomes Cancer 41:38-46.  Reprinted with permission. 
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Figure 4.   Representative G-banded karyotypes from UPCI:SCC131 parental cell line and  
       Clones C and D10.
 
10  In: Reshmi et al. (2003). Genes Chromosomes Cancer 41:38-46.  Reprinted with permission. 
     UPCI:SCC131, passage p18: 78,XY,-X,-3,del(4)(?)x2,+del(4)(q?),+der(5)t(5;7)(?;?)x2[2],der(7)t(X;7) 
    (p11.2;p11.2),+der(7)t(X;7)(p11.2;p11.2),+der(8)t(3;8;13)(?;?;?),del(9)(q12),+der(9)t(9;14)(p21;q12)x2,+der      
    (9)t(9;14)(?;q12),+der(9)t(9;14)(?;?),-10,del(10)(p10),del(11)(p13),+del(11)(q13),hsr(11)(q13),+der(11)t(4;11;17) 
    (?;q13;?)x2,+der(?)t(4;11;17)(?;?;?)x2,+13,-14,-14,-17,der(17)t(2;17)(p13;p11.2),der(17)t(2;17)(q21;q21),+19,  
   +del(20)(q11.2),-21,del(22)(q?); B) UPCI:SCC131, passage 33. Clone C:  78,XY,-X, -2,del(3)(?),+der(3)t(3;16) 
   (q21;p13.1)x2,4,+der(5)t(5;7)(?;?),der(9)t(9;14)(p21;q12),+der(9)t(9;14)(p21;q12)x2,+der(9)t(9;14)(p21;?),+der 
    (9)t(9;14)(?;?)x3,-10,der(10)t(2;10)(?;p10),del(11)(p13),+der(?)t(4;11)(?;?)x2,+der(11)t(4;11;17)(?;q13;?)x2,+der 
    (?)t(11;17)(?;?),-14,der(16)t(3;16)(?;?),-17,-17,+19,+20,-22. 
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Figure 4 (continued).  Representative G-banded karyotypes from UPCI:SCC131 parental  
                                    cell line and Clones C and D11. 
 
 
      Furthermore, most structural chromosome variations were not shared between the UPCI:SCC 
cell lines (Appendix H).   It was challenging to describe the karyotypes of cells that displayed 
marker chromosome evolution, since many chromosomes contained partial broken segments 
from the original chromosomal rearrangements (Fig. 4).  As expected, many G-banded marker 
chromosomes contained similar chromosomal material when painted using SKY, yet were made 
up of different segments from the chromosome of origin.  Marker chromosomes within a clone 
appeared to contain segments of DNA similar to the original parental marker chromosome, but 
distinct from each other (Fig. 3B).  In some cases, marker chromosomes from the original cell 
line appeared to rearrange, or evolve, by combining or breaking into segments and fusing with 
segments from other broken chromosomes (Fig. 3C). 
 
11  In: Reshmi et al. (2003). Genes Chromosomes Cancer 41:38-46.  Reprinted with permission. 
    C) UPCI:SCC131p30 Clone D:  58,X,-X,Y,+Y,+1,-2,der(3)t(3;9)(q12;q13),-4x2,+del(4)(?),-5x2, 
    -6x2,+der(6)t(5;6)(?;q13)x2,-8,+del(9)(p12),+der(9)t(9;14)(p21;q12)x2,-10x2,-11x2,+del(11)(p15q13), 
    +der(11)t(4;11;17)(?;q13hsr;?),-13x2,-14,-15,-17x2,+der(17)t(2;17)(q21;q21),-18,+der(18)t(9;18) 
    (?;p11.2),-19,+der(19)t(4;11;19)(?;q13;p13.3),-20,-21x2,+der(21)t(Y;21)(q12;q11.2),-22. 
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 4.2. ISOLATION OF FRA11F 
 
4.2.1. Mapping FRA11F 
 
Previous studies by our laboratory group (HUANG et al. 2002) identified two breakpoint 
cluster regions flanking the 11q13 amplicon in our OSCC cell lines (Fig. 5). Our current goal 
was to identify the CFS predicted to reside within the breakpoint cluster regions.  We cultured 
normal human blood cells in the presence of aphidicolin followed by exposure to caffeine 
(APCC) in order to enhance for CFS breakage. 
 
 
 
Figure 5.    Proposed common fragile sites flanking the 11q13 amplicon core12. 
 
To be considered located within a fragile site, an individual BAC must be observed as 
having three distinct patterns of hybridization: 1) binding only to the proximal side of the 
chromosome break; 2) binding to both sides of the chromosome break, crossing the fragile site; 
and 3) binding only to the distal side of the chromosome break (Fig. 6).  The most frequently 
expressed breaks meeting these criteria were localized to the region predicted for FRA11F on the 
long arm of chromosome 11 at 11q14.2.  Due to the very low frequency of breakage proximal to 
 
12  CFS predicted from their NCBI data base locations (http://www.ncbi.nlm.nih.gov/LocusLink/).  FRA11A  is a  
     folate-sensitive fragile site at 11q13.3. 
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 the 11q13 amplicon core, we were unable to identify the predicted CFS, FRA11H.  Since the 
purpose of this study was to characterize common fragile sites flanking 11q13, we did not use 
culture conditions that would induce the rare fragile site, FRA11A. 
 
 
 
Figure 6.   Localization of FRA11F BAC RP11-613J18 by FISH in APCC- treated normal blood       
                  cells13  
 
To characterize FRA11F, we carried out FISH using BACs within the previously 
identified distal breakpoint cluster region (HUANG et al. 2002).  The first series of probes showed 
hybridization patterns consistent with their positioning proximal to FRA11F (Fig. 7; Table 4).  
Of 20 BACs, seven (RP11-672A2, 483P13, 98G24, O31F2, 79B7, 118L16, and 89M14) 
hybridized on the centromeric side of the 11q14 break.  Only RP11-372E19 was found to 
localize distal to the FRA11F fragile site.  The remaining BACs within the fragile site region 
(RP11-281H14, 613J18, 19P3, 131C11, 89H11, 141H6, 313I2, 30C9, 18G9, 325I16, 208P3, 
841F15) appeared to hybridize proximally, spanning, and distally to the fragile site with 
relatively equal frequencies (Fig. 7).  We identified a total of 12 BACs within FRA11F, spanning 
a region of 7.5 Mb (Fig. 8; Table 4).   
 
 
 
13  Centromere 11 probe (CEP11, Vysis) in Spectrum-Green™; RP11-613J18 in Spectrum-Orange™ ; 
     BAC probe proximal to the chromatid break at 11q14.2. (B) BAC probe spanning the 11q14.2 break;  
     (C) BAC probe distal to the chromatid break. 
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Table 4.  RP11- BAC clones in and around FRA11F identified by FISH. 
CLONE TOTAL # OF BREAKS PROXIMAL (%) SPANNING (%) DISTAL (%) 
672A2 7 7 (100) 0 (0) 0 (0) 
483P13 14 14 (100) 0 (0) 0 (0) 
98G24 22 22 (100) 0 (0) 0 (0) 
O31F2 22 22 (100) 0 (0) 0 (0) 
79B7 22 22 (100) 0 (0) 0 (0) 
118L16 13 13 (100) 0 (0) 0 (0) 
89M14 20 20 (100) 0 (0) 0 (0) 
281H14 25 17 (68) 8 (32) 0 (0) 
613J18 21 17 (81) 2 (9.5) 2 (9.5) 
19P3 21 14 (66.7) 5 (23.8) 2 (9.5) 
131C11 13 9 (69.2) 2 (15.4) 2 (15.4) 
89H11 27 15 (55.6) 4 (14.8) 8 (29.6) 
141H6 24 7 (29.2) 8 (33.3) 9 (37.5) 
313I2 20 13 (65) 3 (15) 4 (20) 
30C9 16 10 (62.5) 4 (25) 2 (12.5) 
18G9 20 11 (55) 0 (0) 9 (45) 
325I16 16 4 (25) 5 (31.3) 7 (43.7) 
208P3 22 3 (13.6) 1 (4.5) 18 (81.9) 
841F15 15 6 (40) 0 (0) 9 (60) 
372E19 16 0 (0) 0 (0) 16 (100) 
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Figure 7.   Distribution of BAC clones hybridized to APCC induced fragile site breakage in  
                  normal blood cells. 
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Figure 8.   FISH BAC map encompassing FRA11F region14. 
 
 
4.2.2. Analysis of FRA11F in OSCC cell lines 
 
Amplification of chromosomal band 11q13 occurs in approximately one-half of 
squamous cell carcinomas of the head and neck and its subset, OSCC (GOLLIN 2001).  To 
investigate the role of FRA11F in 11q13 gene amplification, we carried out FISH using BACs 
spanning the FRA11F region (RP11- 208P3, 303I2, 841F15, and 281H14) along with CCND1 
(RP11-699M19) in 23 of our OSCC cell lines. 
Of 12 cell lines with CCND1 amplification, we confirmed that nine had breakage, loss, or 
rearrangement of FRA11F (Table 5).  Four of five cell lines without CCND1 amplification 
displayed a normal (control) hybridization pattern for CCND1 and RIN1 (Fig. 9A). OSCC cell 
lines with 11q13 amplification were divided into two categories.  Six cell lines with CCND1 
amplification (UPCI:SCC029B, 056, 078, 084, 131, 136) showed complete loss of distal 11q and 
breakage in the proximal region of FRA11F on the abnormal chromosome 11 (Fig. 9B).  Three  
 
14  FISH BAC map encompassing FRA11F region.  Note that RP11-613J18 lies distal to RP11-281H14  
     and RP11–208P3 partially overlaps with RP11-841F15 and are not included in the map. 
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Table 5.  Metaphase FISH results for OSCC cell lines with and without 11q13 gene  
   amplification. 
 
 
UPCI:SCC 
 
Metaphase FISH 
FRA11F / CCND1 15
 
11q13 
amplification 
status16
003 complex17 + 
016 complex + 
029B loss / hsr + 
032 complex + 
036 not done + 
056 loss / hsr + 
070 complex - 
077 normal - 
078 loss / hsr + 
084 loss / hsr + 
099 not done - 
103 not done + 
105 complex + 
111 complex + 
114 normal + 
116 not done - 
122 complex - 
125 normal + 
131 loss / hsr + 
136 loss / hsr + 
154 complex + 
172 complex + 
182 normal - 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cell lines (UPCI:SCC056, 078, 131) revealed breaks within FRA11F by  FISH using BACs for 
the proximal (RP11-281H14, 313I2) and distal regions of FRA11F (RP11-208P3, 841F15)(Fig. 
 
15  BAC clones RP11-841F15, 208P3, 303I2, and 281H14 used for FRA11F FISH. 
16   +, amplified; - not amplified.  Amplification status based on previous quantitative microsatellite analysis (Huang  
      et al., 2002). 
17  Complex, complex rearrangement of FRA11F and CCND1; loss, loss of FRA11F  sequences; hsr, 11q13  
     amplified in the form of an hsr; normal, FRA11F and CCND1 expressed hybridization pattern observed in  
     normal metaphase cells (i.e., one CCND1 signal centromeric to one FRA11F signal). 
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 9C).  The remaining cell lines expressed complex rearrangements within the 11q13 hsr and 
revealed variations in the hybridization pattern of the FRA11F sequences (Fig. 10).   
 
 
 
 
Figure 9.   Hybridization patterns for CCND1 and FRA11F in OSCC cell lines.   
(A) UPCI:SCC116 showing three normal chromosomes 11 for CCND1 (Spectrum-Orange™) and 
FRA11F (Spectrum-Green™); (B) UPCI:SCC136 expressing two normal copies of chromosome 
11(arrowheads) and one chromosome with amplified CCND1 in the form of an hsr, missing distal 
residual FRA11F sequences (asterisk);  (C) UPCI:SCC078 showing breaks in FRA11F separating the  
proximal RP11-281H14 labeled in Spectrum-Green™ and the distal RP1189-H11 in Spectrum-Orange™.  
Note the loss of distal FRA11F and amplification of proximal FRA11F; (D) UPCI:SCC111 expressing a 
break between proximal FRA11F (Spectrum-Green™, asterisk ) and distal FRA11F regions (Spectrum-
Orange™, arrow).  Marker chromosome with an inverted duplication of CCND1 at the chromosome end 
and centromeric FRA11F sequences (arrowhead).  Broken chromosome with an amplified end may that 
have resulted from breaking of an anaphase bridge. 
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Figure 10. Atypical rearrangement pattern of CCND1 and FRA11F in an OSCC cell line.   
UPCI:SCC016 expressing two normal chromosomes 11 (arrowheads), one derivative chromosome 11  
containing FRA11F sequences only (asterisk), and one derivative chromosome with FRA11F and  
amplified CCND1 in the form of an hsr (arrow). 
 
 
To further understand the involvement of FRA11F in OSCC cell lines with complex 
hybridization patterns, we used three-color FISH for CCND1, proximal FRA11F, and distal 
FRA11F.  BACs for proximal FRA11F (RP11- 281H14, 303I2) were labeled in Spectrum 
Green™, distal FRA11F (RP11- 208P38) in Spectrum Orange™, and CCND1 (RP11-699M19) 
directly labeled in diethylaminocoumarin-5-dUTP 213 (DEAC 213), which is aqua.  Of nine cell 
lines analyzed, seven (UPCI:SCC003, 032, 036, 070, 103, 111, 154) displayed chromosomes 11 
with inverted duplications containing CCND1 and FRA11F sequences (Figs. 11A-B).  Despite 
lack of the inverted duplication pattern in the remaining two cell lines (UPCI:SCC105, 116), 
evidence of breakage or loss of FRA11F was observed together with CCND1 sequences at 
chromosome ends expressing loss of distal 11q (Fig.11C).  Taken together, our data show loss, 
breakage, and inverted duplication hybridization patterns involving FRA11F within OSCC cell 
lines and suggest that breakage at FRA11F may initiate gene amplification through the BFB 
cycle mechanism.   
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Figure 11. Inverted duplication of FRA11F and CCND1 in OSCC cells. 
(A) Three color FISH using CCND1 directly labeled with DEAC213 (aqua), proximal FRA11F sequences 
in Spectrum-Green™ (RP11-281H14, RP11-313I2), and distal FRA11F sequences in Spectrum-Orange™ 
(RP11-208P3) in UPCI:SCC032 metaphase expressing an inverted duplication hybridization pattern and 
isolated hsrs containing CCND1 within the complex chromosome rearrangement.  (B)  UPCI:SCC032 
with an inverted duplication pattern showing CCND1 flanking FRA11F sequences, suggesting a BFB 
cycle model for gene amplification. (C) UPCI:SCC111 expressing a break between the proximal FRA11F 
and distal FRA11F regions.  Marker chromosome expressing a duplication of CCND1 at a chromosome 
end with FRA11F sequences proximal to CCND1, possibly resulting from a broken anaphase bridge. 
 
 
 
4.2.3. Helix flexibility analysis of FRA11F 
 
 
Previous studies have demonstrated that CFS contain regions of high flexibility (MISHMAR 
et al. 1998; MORELLI et al. 2002), although the structural chromatin element conferring this 
fragility remains to be determined.  To determine the flexibility status of FRA11F, we used the 
FlexStab computer program to analyze the 7.5 Mb sequence.  Due to its extremely large size, the 
sequence of FRA11F was divided into two parts for flexibility analysis.  Together, the 7.5 Mb 
region expressed 208 areas with high flexibility (Appendix G, arrows).  Within FRA11F, 
significant deviation was observed compared to the >4.5 SD flexibility value (based on the value 
of the lowest region between 85 [3.5 Mb; x = 10.80; SD= 0.687; P<0.0001] and 123 [4.0 Mb; x = 
10.95; SD= 0.717; P<0.0001]).  Repeat analysis of the FlexStab program for the AT to GC ratio 
revealed that the CG content of FRA11F was approximately 37.4%, representing the lowest GC 
content of other CFS examined to date (MORELLI et al. 2002).  One extremely AT- rich region 
(92%) was identified near a 12 kb sequence gap.  Overall, repetitive elements such as LINEs 
(27.3%), SINEs (10%), LTRs (7.9%) and MERs (3%) accounted for greater than one-half of the 
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 length of the FRA11F sequence, also demonstrating that FRA11F harbors the highest frequency 
of repeat sequences compared to other CFS described in the literature (ARLT et al. 2003; 
CALLAHAN et al. 2003; DENISON et al. 2003; HUANG et al. 1998; MISHMAR et al. 1998; MORELLI 
et al. 2002).   
 
4.3. ASSESSING THE BFB CYCLE AS A MECHANISM FOR 11q13 GENE                           
        AMPLIFICATION  
 
 
The presence of anaphase bridges in dividing tumor cells has been well documented  
(CIULLO et al. 2002; COQUELLE et al. 1997; DEBATISSE et al. 1998; GISSELSSON et al. 2000; 
HELLMAN et al. 2002; HOFFELDER et al. 2004; SAUNDERS et al. 2000). Although the BFB cycle 
model for gene amplification is not new (CIULLO et al. 2002; COQUELLE et al. 1997; DEBATISSE 
et al. 1998; GISSELSSON et al. 2000; HELLMAN et al. 2002; STARK 1993), no previous reports 
have shown direct evidence of an association between anaphase bridging and gene amplification.  
We previously demonstrated anaphase bridges (SAUNDERS et al. 2000) and 11q13 gene 
amplification in the form of an inverted duplication in oral cancer cells (SHUSTER et al. 
2000)(Fig. 12).  Our current investigation tests the hypothesis that 11q13 gene amplification 
occurs through BFB cycles.  If our hypothesis is valid, the presence of anaphase bridges 
containing inverted duplications involving 11q13 amplicon sequences should occur more 
frequently in OSCC cell lines expressing the 11q13 hsr than by chance in OSCC cells without 
11q13 gene amplification. 
 To confirm the BFB model for gene amplification, we carried out FISH using CCND1 
and RIN1 probes on 29 OSCC cell lines with and without 11q13 amplification. Two analyses 
were carried out on the same chamber slide for each OSCC cell line:  1) assessment of gene copy 
number of CCND1 within interphase cells to determine the frequency of copy number of 
CCND1 in each cell line, which enables comparison of 11q13 amplified OSCC cell lines to non-
amplified cell lines; 2) determination of the total number of anaphase bridges within each cell 
line and the number that expressed CCND1 and RIN1 sequences.  For this analysis, OSCC cell  
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Figure 12. Inverted duplication pattern observed in BFB model of gene amplification18. 
 
lines were classified as having 11q13 amplification if 2% or more of interphase nuclei expressed 
more than 10 copies of the CCND1 gene.  Of the OSCC cell lines studied, 18 were determined to 
express 11q13 amplification versus 11 without 11q13 amplification (Fig. 13, Table 6). Among 
those cell lines defined as expressing amplification (n=18), there was a statistically significant 
correlation between the percentage of cells with amplification and the percentage with bridges19.  
The Spearman correlation has 0.40 (p = 0.037) (Appendix I). Thus, it is evident from the scatter 
plot that most of the correlation is due to differences between our “amplified” and “non-
amplified” groups.  
  We observed a high frequency of 11q13 sequences within anaphase bridges in cell lines 
with greater than ten copies of CCND1 (Figs.13-14, Table 6).  The average frequency of 
anaphase bridges expressing 11q13 sequences in cell lines without 11q13 amplification was 
8.2% (range 2.5% to 32.5%) compared to 26% (range 2.4% to 70%) in cell lines with 11q13 
amplification.  Statistical analysis of our results suggested that a significantly higher proportion 
of anaphase bridges contain CCND1 and/or RIN1 in cell lines expressing 11q13 gene 
amplification than in cell lines without 11q13 amplification (p = 0.005; t-test) (Appendix I). The 
finding that genes from within the 11q13 amplicon are present in the form of inverted 
duplications within anaphase bridges confirms that the majority of 11q13 gene amplification in 
OSCC occurs through the BFB cycle mechanism. 
 
18   Red, RIN1 probe; green, CCND1 probe.  Left, normal chromosome 11 expressing one copy each of RIN1 and 
      CCND1; right, chromosome 11 expressing an inverted duplication, in which RIN1 flanks CCND1. 
19   Statistical analyses carried out by Eleanor Feingold, Ph.D., University of Pittsburgh Graduate School of Public  
      Health, Department of Human Genetics. 
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Table 6.  FISH analysis of CCND1 and RIN1 in anaphase bridges and interphase nuclei of OSCC   
               cells. 
 
 
SCC CELL LINE20
 
 
Anaphase bridges  
containing  
inverted duplication pattern 
 
 
Percent of interphase cells 
with CCND1 gene 
amplification 
( >10 copies per cell) 
 
 
CCND1  
Amplification 
UMSCC001 32.5 20.4 + 
UPCI:SCC003 52.5 2.9 + 
UMSCC14A 7.5 0 - 
UPCI:SCC016 25 52.9 + 
UMSCC023 27.5 2 + 
UMSCC025 5 0 - 
UPCI:SCC029B 32.5 89.9 + 
UPCI:SCC032 17.5 74.3 + 
UPCI:SCC036 47.5 100 + 
UPCI:SCC056 15.6† 23.4 + 
UPCI:SCC066 2.5 0 - 
UPCI:SCC070 2.4§  30.7 + 
UPCI:SCC075 0 0 - 
UPCI:SCC077 0ψ 0 - 
UPCI:SCC078 2.4§  78.2 + 
UPCI:SCC084 24.4 52 + 
UPCI:SCC103 70 39 + 
UPCI:SCC104 15 6 + 
UPCI:SCC105 25.6 0 - 
UPCI:SCC111 25 9 + 
UPCI:SCC114 21.2 ND ND 
UPCI:SCC116 12.5 0 - 
UPCI:SCC122 0 0.8 - 
UPCI:SCC125 12.5 8.1 + 
UPCI:SCC131 25 78.6 + 
UPCI:SCC136 15 35.6 + 
UPCI:SCC142 17.5 0 - 
UPCI:SCC154 12.5 0 - 
UPCI:SCC172 32.5 0 - 
UPCI:SCC182 ND 26 + 
 
 
20 UM, University of Michigan; UPCI, University of Pittsburgh Cancer Institute. 
†   Only 32 anaphase bridges available for analysis. 
§   A total of 41 anaphase bridges analyzed. 
ψ  Only 24 anaphase bridges available for analysis. 
§   A total of 41 anaphase bridges analyzed. 
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Figure 13. 11q13 gene amplification in UPCI:SCC cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  Inverted duplication pattern of 11q13 gene amplification in two anaphase bridges 
between dividing cells21. 
 
21  Anaphase bridges in UPCI:SCC103 cell line.  RIN1, Spectrum-Orange™; CCND1, Spectrum-Green™. 
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5. DISCUSSION 
 
5.1. CIN IN OSCC CLONES 
 
Epithelial carcinomas, such as SCCHN and their subset, OSCC, frequently exhibit 
complex karyotypes.  The karyotypes of OSCC cells contain numerical and structural 
abnormalities, including balanced and unbalanced translocations, deletions, dicentric 
chromosomes, gene amplification in the form of hsrs, and isochromosomes.  Although individual 
cells may express unique chromosomal rearrangements, classical and molecular cytogenetic 
analyses of OSCC cells have described several clonal aberrations including loss of chromosomal 
regions 9p21, 3p, 17p13, 11q13 amplification and/or loss of regions 4q26-q28, 6p, 8p23, 13q21, 
and/or 14q24 (GOLLIN 2001).  As a result of these deletions and amplifications, karyotypes may 
express abnormalities such as whole arm chromosome loss and/or isochromosome formation of 
5p, 8q, 9q, and others.  Initial karyotype analysis of our OSCC cell lines by Christa Lese Martin 
revealed that cells were near-triploid and contained chromosome abnormalities typically 
observed in OSCC, along with various other structural alterations. Our findings are consistent 
with those of Carey et al. (1993), Shackney et al. (1995), and Jin et al. (2002), and conform to 
the observation that late-stage, malignant cancer cells contain between 60 and 90 chromosomes.    
There are a number of ways in which cancer cells may become tetraploid, including: 
mitotic arrest, failed cytokinesis, and spindle defects (failed chromosome alignment followed by 
division of tetraploid chromosome number into several micronuclei), or endoreduplication 
(OKSALA and THERMAN 1974; SHACKNEY et al. 1995).  This event, followed by subsequent 
chromosome loss (reviewed in Nigg, 2002) may account for the near-triploid chromosome 
number observed in our OSCC cell lines.  In contrast to the usually quite stable karyotype of 
cells in hematological cancers (HEIM and MITELMAN 1995), the CIN observed as aneuploidy 
between individual cells has been demonstrated in a variety of carcinomas (JIN et al. 2002; 
LENGAUER et al. 1997b; PIHAN and DOXSEY 1999; SHACKNEY et al. 1995).  Previous 
investigations from our laboratory suggest that the progressive numerical alterations in OSCC 
cells may result from defects in the mitotic apparatus and aberrant centrosomes (QUINTYNE et al. 
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 2005; REING et al. 2004; SAUNDERS et al. 2000).  Here we combined classical cytogenetics, 
FISH, and SKY, to compare and contrast clones derived from two of our OSCC cell lines.  
Consistent with previous investigations of tumor evolution (ALBERTSON et al. 2003), cell lines in 
our study demonstrated remarkable karyotype stability between the parental cell lines and 
daughter clones, despite expressing variations in chromosome number, unique rearrangements, 
and marker chromosomes that appeared to “evolve” by combining with segments of other broken 
chromosomes, giving rise to complex rearrangements.   
Karyotype analysis of our OSCC parental cell lines and clones revealed that centromere 
copy number similarities between the individual clones observed by FISH did not necessarily 
represent the same chromosome within each cell (Fig. 3).   Marker chromosome evolution in 
OSCC cells is consistent with previous studies demonstrating that mechanisms promoting CIN 
remain active in late stage tumor cells.  Such factors include anaphase bridges resulting from 
telomere defects (GISSELSSON et al. 2002; GORDON et al. 2003) cell lines in our study 
demonstrated remarkable karyotype stability between the parental cell lines and daughter clones, 
despite expressing variations in chromosome number, unique rearrangements, and marker 
chromosomes that appeared to “evolve” by combining with segments of other broken 
chromosomes, giving rise to complex rearrangements.   
Karyotype analysis of our OSCC parental cell lines and clones revealed that centromere 
copy number similarities between the individual clones observed by FISH did not necessarily 
represent the same chromosome within each cell (Fig. 3).   Marker chromosome evolution in 
OSCC cells is consistent with previous studies demonstrating that mechanisms promoting CIN 
remain active in late stage tumor cells.  Such factors include anaphase bridges resulting from 
telomere defects (GISSELSSON et al. 2002; GORDON et al. 2003), dicentric chromosomes 
(HACKETT et al. 2001), defects in DNA damage response pathways (BASSING et al. 2003; 
CELESTE et al. 2003; PARIKH and GOLLIN unpublished work; SAUNDERS 2005; SMITH et al. 
1998) and aneuploidy resulting from multipolar spindles and/or centrosome aberrations 
(GISSELSSON et al. 2002; REING et al. 2004; SAUNDERS 2005; SAUNDERS et al. 2000).  In 
addition, it is possible that marker chromosome evolution may have arisen through double- 
stranded breaks (DSBs), some of which involve chromosomal fragile sites (RESHMI and GOLLIN 
2005). DSBs in neoplastic cells have been shown to enhance the inactivation of tumor suppressor 
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 genes, susceptibility to viral integration, and the capability of acquiring drug resistance through 
gene amplification.   In experimental mammalian cells and in human oral cancer cells, we and 
others have demonstrated that breakage-fusion-bridge (BFB) cycles (MCCLINTOCK 1938; 
MCCLINTOCK 1939) may result in gene amplification (CIULLO et al. 2002; COQUELLE et al. 
1997; HELLMAN et al. 2002; SHUSTER et al. 2000) as well as chromosome missegregation and 
aneuploidy (GISSELSSON et al. 2002), resulting in all forms of chromosomal instability.   
Consistent with our current findings, recent studies of independently derived clones from 
the UPCI:SCC040  cell line demonstrated similar segregational defects between daughter clones 
and parental cell populations (REING et al. 2004).  The frequency of metaphase cells with lagging 
chromosomes, anaphase bridges, and anaphase cells containing lagging chromosomes was 
remarkably conserved within the five daughter clones, although a somewhat higher incidence of 
multipolarity was observed.  The difference in overall occurrence of segregational defects 
between the UPCI:SCC040 parent and cloned cells when compared to the UPCI:SCC103 cell 
line was striking.  Unfortunately, those clones were not available for karyotype analysis.  
However, we show that despite common loss and gain of genetic material characteristic of 
OSCC tumors (CAREY et al. 1993; GOLLIN 2001; JIN et al. 2002; SHACKNEY et al. 1995), 
additional clonal alterations in chromosome structure  may be present within parental and 
daughter cell lines, but rarely between the parental cell lines themselves.  In addition, no two 
cells from the parent or daughter clones of either cell line expressed the identical karyotype.  
Although various mechanisms leading to genetic instability have been described, their overall 
influence with respect to carcinogenesis remains largely unknown. While defects in cell cycle 
checkpoints often provide a green light for abnormal tumor cells to continue through the cell 
cycle, other mechanisms, including BFB cycles, gene amplification, chromosomal fragile sites, 
and defects in the DNA repair of DSBs can be involved in promoting CIN.  Thus, chromosomal 
instability in the form of marker chromosome evolution may result from both intrinsic 
chromosomal factors, such as dicentric chromosomes involved in BFB cycles (MCCLINTOCK 
1938; MCCLINTOCK 1939), and extrinsic chromosomal factors, including multipolar spindles 
(SAUNDERS 2005; SAUNDERS et al. 2000). 
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 5.2. BREAKAGE AT FRA11F AS AN INITIATING EVENT IN 11q13 GENE            
         AMPLIFICATION 
 
We and others have shown that amplification of band 11q13 is generally observed in the 
form of an hsr involving band 11q13 (BARTKOVA et al. 1995; GOLLIN 2001; JIN et al. 1998b; 
LESE et al. 1995; MICHALIDES et al. 1995).  Other investigators have demonstrated that 
intracellular gene amplification may be promoted by exposing cells to certain clastogens or 
hypoxia, which cause DNA strand breaks (KUO et al. 1998; RICE et al. 1986; SINGER et al. 2000; 
TONNIES et al. 2003).  In an attempt to repair these breaks, sister chromatids may fuse together 
and ultimately form a dicentric chromosome (Fig. 15).  If both centromeres remain active, during 
anaphase the centromeres could either migrate to the same pole or opposite poles.  In the event 
that the centromeres are pulled in opposing directions, an anaphase bridge is formed between the 
two dividing cells.   
There are three possible fates for broken dicentric chromosomes resulting from anaphase 
bridging. The chromosome ends may 1) be repaired or stabilized through the addition of 
telomere sequences by telomerase; 2) fuse with other broken chromosome ends, forming 
derivative chromosomes that may or may not contain two centromeres; 3) fuse with each other, 
forming another dicentric chromosome containing an inverted duplication pattern of genes.  In 
the event of further dicentric chromosome formation, anaphase bridges would continue through 
subsequent cell divisions, promoting BFB cycles. Previous studies by our laboratory 
demonstrated expression of the 11q13 amplicon in the form of an inverted duplication in which 
multiple copies of CCND1 were flanked by RIN1 (SHUSTER et al. 2000).  Further investigation of 
our OSCC cell lines revealed dicentric anaphase chromatin bridges (SAUNDERS et al. 2000).  
Combined, these findings suggested that 11q13 gene amplification occurs via BFB cycles which 
may result from chromosome breakage.   
There has been increasing evidence that breakage within highly flexible regions of the 
genome known as common fragile sites (CFS) may initiate gene amplification in human tumors 
(CIULLO et al. 2002; COQUELLE et al. 1997; PIPIRAS et al. 1998; STARK 1993; WINDLE et al. 
1991).  We therefore set out to determine whether or not our OSCC cell lines expressed a 
common region prone to breakage along chromosome 11 that could trigger 11q13 gene 
amplification.  Physical mapping studies of the 11q13 amplicon using QuMA on 30 OSCC cell 
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 lines revealed proximal and distal breakpoint regions between D11S4178 and D11S5031 and 
D11S5037 and D11S1314, respectively (HUANG et al. 2002).   Interestingly, FRA11H and 
FRA11F have been identified as CFS flanking the region harboring CCND1.  Taken together, we 
hypothesized that one or both CFS may be highly prone to breakage in OSCC cells.   
In our current investigation, we identified and characterized a CFS distal to the 11q13 
amplicon.  We show the most frequently broken CFS on the long arm of chromosome 11 to be 
FRA11F at 11q14.2.  The very low occurrence of breakage between the centromere and 11q13  
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Figure 15. Proposed BFB model for OSCC cells22. 
 
 
 
 
22   (A) Proposed BFB model for BACs proximal to 11q13 amplicon in UPCI:SCC040.  Partial metaphase  
      cell shows two chromosomes with an inverted duplication of the 11q13 amplicon.  Note BFB model  
      schematic represents only one-half of the amplicon expressed in each chromosome. 
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 prevented physical mapping and characterization of the more proximal CFS, FRA11H 
(http://www.ncbi.nih.gov/entrez/query.fcgi?db=gene). Due to the folate-sensitive nature of the 
rare FRA11A fragile site, we were unable to physically map its exact sequence or determine its 
role in 11q13 gene amplification.  Unlike common fragile sites, rare fragile sites cannot be 
induced in all individuals.  A previous report suggested the presence of increased breakage of 
FRA11A in young smokers (KAO-SHAN et al. 1987).  However, confirmation of breakage 
specifically within the FRA11A fragile site was not discussed.  These investigators may actually 
have been observing breakage of the FRA11F common fragile site.  If FRA11A is confirmed to 
break at a higher frequency in blood cells of smokers, physical mapping of FRA11A may be 
feasible.  Following the characterization of FRA11F, determining its role, if any, in OSCC gene 
amplification may then be possible.   
To compare the physical characteristics of FRA11F to those identified for other CFS, we 
characterized the sequence corresponding to the FRA11F region we identified by FISH 
(http://www.ncbi.nih.gov/entrez/query.fcgi?db=gene).  A total of 12 BACs spanning 7.5 Mb 
corresponded to FRA11F, including a small 12 kb sequence gap in the genome map.  We showed 
that breakage of FRA11F in APCC- induced peripheral blood cells is equally distributed among 
BACs spanning FRA11F (Figs. 7-8, Table 4).  Our findings are consistent with earlier 
observations that the active “center” of a fragile site exhibits proximal and distal breakage with 
relatively equal frequencies (CALLAHAN et al. 2003).    CFS regions have been shown to have a 
GC content (41%) similar to the average GC content in the human genome (MORELLI et al. 2002; 
VENTER et al. 2001). We found the GC content of the 7.5 Mb region defining FRA11F to be 
37.4%, less than that described for FRA3B, FRA6E, FRA6F, FRA7H, and FRA16D (MORELLI et 
al. 2002).  Since repetitive DNA sequences are also thought to play a role in contributing to the 
instability of fragile site regions, we analyzed FRA11F for these elements.  We observed that 
repeat sequences comprised approximately one-half of the DNA content for FRA11F, which is a 
larger percentage than those identified in the five CFS characterized previously (MORELLI et al. 
2002).  Since AT base pairs are held together by one less hydrogen bond than GC base pairs, the 
increased percentage of AT-rich sequences within FRA11F suggests it may also express a higher 
susceptibility to breakage compared to other CFS.   
Currently, there are 17 known genes within FRA11F 
(http://www.ncbi.nih.gov/entrez/query.fcgi?db=gene).  The majority of genes (76%) reside in the 
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 proximal 5.7 Mb region of FRA11F.  Both DLG2 and PICALM, a gene identified as a partner for 
AF10 in the t(10;11)(p13;q14) in myeloid and lymphoid leukemias (DREYLING et al. 1996), 
contain coding regions within proximal FRA11F.  Members of the lethal(1)discs large (DLG) 
gene family are able to convert organized epithelial tissues into muddled, undifferentiated 
hyperplastic overgrowths when mutated in Drosophila (reviewed in Watson et al., 1994).  Of the 
tumor suppressor genes identified in Drosophila, only DLG and l(2)gl (lethal(2)giant larvae) 
have been proposed as candidates  having a role in human cancers, since loss of function of 
either results in neoplastic transformation (DE LORENZO et al. 1999). One OSCC cell line, 
UPCI:SCC078, demonstrated amplification within the proximal region of FRA11F and loss of 
distal 11q, including distal FRA11F.  Dual-color FISH for BACs spanning the proximal and 
medial FRA11F regions (RP11-281H14 and RP11-89H11) confirmed that a break occurred 
within the region of FRA11F containing DLG2 (Fig. 9C). Our finding that the majority of OSCC 
cell lines expressing 11q13 amplification display breakage within proximal FRA11F suggests 
that disruption and/or loss of DLG2 as well as other neighboring genes may play a role in OSCC 
development and/or progression.    
Amplification of 11q13 in OSCC may be the consequence of losing genes distal to 11q13 
following breakage at FRA11F, and as a secondary event resulting from the attempt of a 
damaged cell to repair itself through sister chromatid fusion (CIULLO et al. 2002; HELLMAN et al. 
2002).  The latter event would result in a dicentric chromosome containing inverted repeats of 
11q13 genes within the amplicon.  If both centromeres remained active on the newly formed 
chromosome, they may segregate to opposite poles during anaphase resulting in an anaphase 
bridge (MCCLINTOCK 1938; MCCLINTOCK 1939).  Our current study suggests that broken 
chromosome ends containing FRA11F sequences or chromosome ends with an increase in copy 
number of genes proximal to lost FRA11F regions, eliciting subsequent BFB cycles and 
chromosomal instability.  We previously observed dicentric chromosomes and an inverted repeat 
gene pattern of RIN1 and CCND1 within OSCC cell lines expressing CCND1 amplification 
(SHUSTER et al. 2000).  In addition, we identified variable breakpoint cluster regions in the 
11q13 hsr as well as genetic heterogeneity within the amplicon of our OSCC cells (Figs. 9B-D, 
10, 11).   These findings provide further support for the hypothesis proposed by Hellman and 
colleagues (HELLMAN et al. 2002), that intrachromosomal gene amplification in the form of an 
hsr may occur by chance due to the location of the amplified genes relative to a CFS.   
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 Our current study reveals that loss, breakage, and/or inverted duplications of FRA11F 
occurred in 15 of 23 cell lines examined. Therefore, we suggest that breakage of distal FRA11F 
at 11q14.2 may be an important event leading to amplification of the 11q13 region.  We show 
that spontaneous breakage of FRA11F contributes to the complexity of the 11q13 amplicon 
through BFB cycles as evidenced by the presence of inverted duplications within the amplified 
region (Fig. 16). These data are consistent with those of Ciullo and colleagues (CIULLO et al. 
2002), in which breakage of FRA7I in a T47 breast cancer cell line expressed gene amplification 
in the form of an hsr containing the PIP gene resulting from  BFB cycles.  
 
Figure 16. Metaphase FISH demonstrating inverted duplication of CCND1 and FRA11F  
      within the 11q13 amplicon23. 
 
 
23  UPCI:SCC032 expressing an inverted duplication pattern and one normal chromosome 11.  CCND1 in aqua,   
     proximal FRA11F sequences in Spectrum-Green (RP11-281H14, RP11-313I2), and distal FRA11F sequences in   
     Spectrum-Orange (RP11-208P3).  Panel shows 1) a merged image of CCND1 with both proximal and distal  
     FRA11F sequences; 2) distal FRA11F only; 3) proximal FRA11F only; 4) CCND1 only; 5) proximal FRA11F in  
     Spectrum-Green and CCND1 in aqua; 6) distal FRA11F in Spectrum-Orange and CCND1 in aqua.  Diagram  
     depicting an inverted duplication pattern.  Filled rectangle, centromere; circle, CCND1; square, proximal    
     FRA11F sequences; triangle, distal FRA11F sequences. 
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There are many issues that remain unresolved regarding the role of CFS in human cancer.  
For example, why does loss of one CFS result in gene amplification while loss of another does  
not?  Why have individual tumor types been shown to contain LOH at multiple CFS (DENISON et 
al. 2002; PETURSDOTTIR et al. 2004)? Does loss of a specific region or gene(s) within a particular 
CFS confer a selective advantage for particular tumor types?  With the exception of FRA3B 
(HUEBNER and CROCE 2003), the mechanisms by which individual CFS promote neoplastic 
transformation and progression are only starting to be examined. Due to resources that have 
become currently available through the human genome project, characterization of other CFS is 
more feasible. 
Previous work by Casper et al. (CASPER et al. 2002) demonstrated the importance of ATR 
and BRCA1 in maintaining fragile site stability.  Their study concluded that fragile sites may 
result from defects in genes involved in DNA repair.  By knocking down BRCA1 through RNA 
interference, Arlt et al. (ARLT et al. 2004) showed that mouse and human cells with almost no 
functional BRCA1 have elevated expression of CFS.  Furthermore, they provide evidence that 
proper functioning of BRCA1 is required for the G2/M checkpoint to identify late replicating 
DNA, including CFS. These observations raise the question of whether or not breakage at CFS is 
causal in particular cancers, or if fragile site breakage is merely a reflection of faulty repair 
machinery that is unable to detect and correct these regions of stalled replication prior to cell 
division. Given that 1) close to half of all oral cancer cases express 11q13 amplification which is 
associated with decreased survival and poor response to treatment (AKERVALL et al. 1997; 
FORASTIERE et al. 2001; GOLLIN 2001; MICHALIDES et al. 1995) and 2) current cancer therapies 
employ agents known to cause chromosome breaks that may result in gene amplification of 
oncogenes within cells of relapsing individuals (CHAMPEME et al. 1995), a further understanding 
of the biological mechanism(s) involved in the amplification process is critical. 
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5.3. EVIDENCE IN SUPPORT OF A BFB CYCLE MODEL FOR 11q13 GENE  
         AMPLIFICATION 
 
The presence of anaphase bridges has been shown to be a useful biomarker for defects in 
chromosome segregation (HOFFELDER et al. 2004; LUO et al. 2004; MONTGOMERY et al. 2003). 
We and others have demonstrated that anaphase bridges contribute to CIN through gene 
amplification (GISSELSSON et al. 2000) and micronucleus formation with chromosome 
fragmentation and/or loss (GISSELSSON et al. 2000; HOFFELDER et al. 2004; KAYAL et al. 1993; 
LIVINGSTON et al. 1990; LUO et al. 2004; SAUNDERS et al. 2000; STICH et al. 1992).  We further 
suggest that anaphase bridging promotes marker chromosome evolution (RESHMI et al. 2004), as 
this phenomenon has been reported previously in tumors exhibiting CIN (MONTGOMERY et al. 
2003).  However, the precise mechanisms by which anaphase bridges promote these events in 
specific tumor types remain under investigation.   
We recently showed that breakage at a common fragile site, FRA11F, is associated with 
11q13 gene amplification in oral cancer cells.  In addition, we identified inverted duplications of 
CCND1 flanked by RIN1 within the 11q13 amplicon (SHUSTER et al. 2000), and broken 
chromosomes with amplified chromosome ends (Fig. 9D).  Combined, our observations support 
the BFB cycle model for gene amplification.  The current study links the findings of our previous 
work by providing evidence that inverted duplication sequences of RIN1 and CCND1 expressed 
in metaphase chromosomes are also expressed within a high percentage of anaphase bridges in 
OSCC cells.  Here we carried out FISH using CCND1 and RIN1 probes on 29 OSCC cell lines 
with and without 11q13 amplification. On each chamber slide, we: 1) assessed CCND1 gene 
copy number within interphase cells to confirm and compare 11q13 amplified OSCC cell lines 
from non-amplified cell lines in this study; 2) quantified CCND1 and RIN1 sequences within 
anaphase bridges within each cell line.   OSCC cell lines negative for 11q13 amplification 
expressed a lower frequency of CCND1 and RIN1 sequences in anaphase bridges compared to 
cell lines with greater than ten copies of CCND1 (Figs.13-14, Table 6).  The average frequency 
of anaphase bridges expressing 11q13 sequences in cell lines without 11q13 amplification was 
8.2% (range 2.5% to 32.5%) compared to 26% (range 2.4% to 70%) in cell lines with 11q13 
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 amplification.  Statistical analysis of our results suggested that a significantly higher proportion 
of 11q13 amplicon sequences occur in anaphase bridges of cell lines expressing 11q13 gene 
amplification than in cell lines without 11q13 amplification (p = 0.005; t-test) (Appendix I). The 
finding that genes from within the 11q13 amplicon are present in the form of inverted 
duplications within anaphase bridges confirms that the majority of 11q13 gene amplification in 
OSCC occurx through the BFB cycle mechanism. 
Although we present for the first time a direct association between gene amplification and 
anaphase bridges in cancer cells, our current investigation cannot rule out the presence of other 
segregational defects contributing to anaphase bridges.  Chromosome segregation requires 
properly functioning cell cycle checkpoints, mitotic machinery, and an efficient anaphase 
promoting complex (APC) to ensure that each daughter cell receives equal and identical 
chromosome material from their mother cell.   
One of the checkpoints, the mitotic spindle checkpoint, ensures bipolar attachment of 
kinetochores to microtubules prior to chromosome separation at anaphase (HOYT 2001).  If all 
kinetochores are properly attached, the checkpoint signals activation of the APC to continue with 
cell division.  In cells with properly functioning spindle checkpoints, it has been demonstrated 
that a single misaligned kinetochore is able to prevent cell cycle progression (WELLS and 
MURRAY 1996). Genes included in this pathway are the mitotic arrest deficient (Mad) Mad1, 
Mad2, Mad3/BubR1, budding uninhibited by benzimidazole (Bub) Bub1, Bub3, Mps1 and 
Aurora-B (reviewed in (DRAVIAM et al. 2004)). Proteins involved in the spindle checkpoint have 
shown evolutionary conservation, highlighting the importance of maintaining the delicate 
balance of genetic material within living cells (HOYT et al. 1991; LI and MURRAY 1991).    
Protein homologues of the Mad and Bub families have been shown to identify and associate only 
with lagging chromosomes that fail to align properly (CHEN et al. 1996; JIN et al. 1998a; 
TAYLOR et al. 1998; TAYLOR and MCKEON 1997).  Consistent with this idea is the suggestion 
that lagging chromosomes may facilitate binding of Mad2 to Cdc20, inhibiting progression into 
anaphase (GORBSKY 2001; SHAH and CLEVELAND 2000; YU 2002). If lagging chromosomes are 
detected, Mad2 of the spindle checkpoint prevents separation of sister chromatids and 
degradation of cyclins by inhibiting APC-Cdc20 (YU 2002).  Other studies have suggested that 
the microtubule motor, dynein, may play an important role in checkpoint inactivation by 
assisting in the transport of checkpoint proteins between the spindle poles and kinetochores 
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 (reviewed in (BHARADWAJ and YU 2004).  However, despite the findings that mutations in hBub 
are present in cancer cells expressing CIN (CAHILL et al. 1998), loss of genes within cell cycle 
checkpoints by themselves has not been shown to directly cause segregational defects.   
 The APC is a ubiquitin ligase that targets degradation of cell cycle proteins to enable 
cells for mitotic exit (CASTRO et al. 2005).  Prior to anaphase, a cohesin complex prevents 
premature separation of replicated sister chromatids joined in S phase until they enter anaphase 
(ZOU et al. 1999).  Cohesin has been shown to contain several subunits, including Scc1p/Mcd1p, 
Scc3p, Smc1p,  and Smc3p (MORRISON et al. 2003).  These proteins form cohesin complexes 
along many sites on each chromosome (MICHAELIS et al. 1997).  In humans, the cohesin subunits 
include: SMC1, SMC1β, SMC3, SCC1(RAD21), REC8, SA1, SA2, STAG3 (reviewed in 
Nasmyth, 2001).  To enter anaphase, sister chromatids are separated by breakdown of the 
cohesin complex (Fig. 17).  This event requires activation of securin which in turn degrades 
separase, then cleaves the cohesin complex at its subunits, resulting in sister chromatid 
separation (UHLMANN et al. 1999; UHLMANN et al. 2000; YANAGIDA 2000).  Cohesin is essential 
for facilitating attachment of microtubules from opposite poles to sister centromeres (TANAKA et 
al. 2000).  Mutant cohesion has been shown to promote monopolar attachment of sister 
centromeres, resulting in chromosome missegregation (GUACCI et al. 1997; MICHAELIS et al. 
1997; UHLMANN and NASMYTH 1998).  Errors of cohesin reformation have also been associated 
with CIN (HOQUE and ISHIKAWA 2002; RAO et al. 2001; UHLMANN 2004). One study by 
Jallepalli et al. (2001) observed anaphase bridges, budding nuclei, and CIN as a result of 
inactivating both copies of the securin/pituitary tumor-transforming 1 (PTTG1) gene24,  in a 
human colorectal cancer cell line.  This suggests that cells are unable to carry out sister 
chromatid separation in the absence of separase cleavage by securin.  In addition, failure of 
separase to cleave the cohesin complex may itself lead to bridge formation (HAERING et al. 
2004).   
 
24  The official symbol and name for the human SECURIN gene. 
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Figure 17. Degradation of the APC for chromosome separation25. 
 
 
In order for anaphase to proceed, several proteins must ubiquitinated by APC and 
subsequently degraded by a proteasome protein complex. In fission yeast, two mutants of 
centromere enhancer of position effect (cep) genes that are necessary for proteasome structure 
were shown to prevent sister chromatid separation, resulting in missegregation of chromosomes 
(JAVERZAT et al. 1999).  Although the mechanism for this phenomenon is unclear, further studies 
will elucidate whether or not one or more protein targets are necessary for the resulting 
phenotype.  However, studies in Drosophila revealed that mutations in a single ubiquitin-
conjugating enzyme, UbcD1, resulted in dramatic increases in telomere associations (CENCI et 
al. 1997).  Taken together, these studies suggest that anaphase bridges may also result from 
defective proteasome function. 
 There is also evidence to suggest an association between anaphase bridge formation and 
segregational errors due to abnormal  numbers of mitotic spindles (GISSELSSON et al. 2002; 
GISSELSSON et al. 2004).  Previous investigations from our laboratory identified the presence of 
multipolar spindles in OSCC cells (SAUNDERS et al. 2000).  We recently demonstrated that 
 
25  Red connected circles, cohesion complex; blue arrows, tension from microtubules. 
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 increases in the spindle protein, NuMA, plays a major role in promoting spindle multipolarity 
(QUINTYNE et al. 2005).   
Although centrosome amplification is not essential for multipolar spindle formation 
(reviewed in Saunders, 2005), multipolar spindles have been shown to result from increased 
centrosomal amplification in mice mutant for Brca1 (DENG 2002; XU et al. 1999b) and Brca2 
(TUTT et al. 1999; XU et al. 1999b).  In addition, both overreplication and failed cytokinesis 
resulting in centrosome amplification have been associated with increases in anaphase bridging. 
In order for the APC complex to function properly, various substrates are required. These 
include, but are not limited to, Cyclin B, Cdc5/Plk1/Polo kinase, Cdc20, Aurora A kinase 
(CASTRO et al. 2005).  Studies have shown that aberrant  protein expression within the cell cycle, 
such as amplified Aurora A, Aurora B, or Plk1 may promote centrosome amplification (ZHOU et 
al. 1998).  Interestingly, centrosome amplification and anaphase bridges may also be caused by 
overexpression of the DNA damage response genes, ATM and ATR, as well as other associated 
genes and proteins within these pathways (SAUNDERS et al. 2000; SMITH et al. 1998).   
It was demonstrated previously that the majority of broken chromosome ends resulting 
from anaphase bridges are repaired by non-homologous end joining (NHEJ)(reviewed in 
(PASTINK et al. 2001).  The NHEJ pathway includes DNA-dependent protein kinase (DNA-PK), 
Ku70, Ku80, DNA ligase-4 and XRCC4.  Through this repair pathway, joining of heterologous 
chromosome ends may result dicentric chromosomes that are then pulled to opposite poles at 
anaphase, resulting in an anaphase bridge.  Subsequent chromosome end fusions may occur, 
promoting BFB cycles and either 1) gene amplification through chromosomes that have 
undergone sister chromatid fusion, forming inverted duplication segments and homogeneously 
staining regions, or 2) CIN due to formation of other, nonhomologous dicentric chromosomes 
(with different chromosomal origins) (ZHIVOTOVSKY and KROEMER 2004).  Current 
investigations are ongoing to determine the role of the specific genes in the NHEJ pathway in 
anaphase bridge formation resulting in CIN (C. Acilan and W.S. Saunders, unpublished work). 
There are various biological mechanisms that promote anaphase bridge formation.  These 
include: 1) formation of dicentric chromosomes through telomere dysfunction  (GISSELSSON et 
al. 2000; GORDON et al. 2003; HACKETT et al. 2001), 2) centrosome amplification (DENG 2002; 
SAUNDERS 2005; TUTT et al. 1999; XU et al. 1999b; ZHOU et al. 1998), and 3) defects in genes or 
proteins associated with DNA damage response pathways (PARIKH and GOLLIN unpublished 
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 work; SAUNDERS 2005; SMITH et al. 1998). In addition, previous investigations have suggested a 
BFB cycle model for gene amplification (CIULLO et al. 2002; COQUELLE et al. 1997; HELLMAN 
et al. 2002; MCCLINTOCK 1938; MCCLINTOCK 1939; SHUSTER et al. 2000), proposing that gene 
amplification occurs through anaphase bridges resulting from dicentric chromosomes formed 
from sister chromatid fusion of broken chromosome ends. We and others have shown the 
presence of anaphase bridges in cancer cells (GISSELSSON et al. 2000; HOFFELDER et al. 2004; 
LUO et al. 2004; MONTGOMERY et al. 2003; REING et al. 2004; SAUNDERS et al. 2000).  
However, until now, a direct association between anaphase bridges and gene amplification has 
not been demonstrated.    Our current observation of inverted duplication sequences within 
anaphase bridges of OSCC cells expressing 11q13 gene amplification provide conclusive 
evidence that at least some cases of gene amplification occur through the BFB mechanism.  
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 6.     SUMMARY 
 
 
Chromosomal instability has been shown to play a significant role in the progression of 
human malignancies.  Various factors may induce CIN through DNA double strand breaks in 
combination with a defective DNA damage response.  In the absence of functioning cellular 
checkpoints, neoplastic cells with intrinsic chromosomal abnormalities are able to continue 
through cell division, giving rise to daughter cells that do not resemble each other or their mother 
cell.  Similarly, extrinsic cytoskeletal aberrations such as multipolar spindles (SAUNDERS et al. 
2000), alterations in centrosome number (GISSELSSON et al. 2002; SAUNDERS 2005; ZHOU et al. 
1998) or increased expression of centrosomal proteins (BERGOGLIO et al. 2002; GRITSKO et al. 
2003; LI et al. 2003; LINGLE et al. 2002; PIHAN et al. 1998; PIHAN et al. 2001; SATO et al. 2001; 
ZHOU et al. 1998) may play an important role in CIN.  Regardless of how the observed mutator 
phenotype originates, propagation of these cells or chromosomal defects is maintained through 
BFB cycles, which may in turn promote CIN through gene amplification (CIULLO et al. 2002; 
COQUELLE et al. 1997; HELLMAN et al. 2002; SHUSTER et al. 2000). 
We investigated three patterns of CIN observed in OSCC: numerical chromosomal 
aberrations, structural chromosomal alterations, and gene amplification.  The current findings 
demonstrate CIN in oral cancer cells, and further elucidate one mechanism by which CIN occurs.  
Building on previous work from our laboratory involving identification and characterization of 
the 11q13 amplicon (HUANG et al. 2002; LESE et al. 1995; SHUSTER et al. 2000) along with 
recent findings that cigarette smoke condensate induces double strand breaks in normal cells 
(LUO et al. 2004),  we now suggest that breakage at the common fragile site, FRA11F, may play 
a key role in initiating gene amplification in OSCC cells.  We mapped FRA11F to a 7.5 Mb 
region distal to the 11q13 amplicon and suggest that spontaneous breakage of FRA11F 
contributes to the complexity of the 11q13 amplicon through BFB cycles by showing loss, 
breakage, and rearrangements of FRA11F within OSCC cell lines expressing 11q13 gene 
amplification.  
Our laboratory and others have suggested that gene amplification occurs through BFB 
cycles (CIULLO et al. 2002; COQUELLE et al. 1997; MCCLINTOCK 1938; MCCLINTOCK 1939; 
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 SHUSTER et al. 2000), in which gene amplification occurs through anaphase bridges resulting 
from dicentric chromosomes formed by sister chromatid fusion of broken chromosome ends.  
Our current study demonstrates that sequences harbored within the 11q13 amplicon are present 
in the form of inverted duplication sequences. In addition, the inverted duplication sequences 
were found to frequently occur within anaphase bridges of OSCC cells expressing 11q13 gene 
amplification.    
This investigation shows evidence to support our initial hypotheses that 1) breakage at a 
chromosomal fragile site may be an initial step for 11q13 gene amplification, and 2) gene 
amplification at 11q13 occurs through BFB cycles in OSCC.  Although involvement of FRA11A 
in 11q13 gene amplification cannot be ruled out by the current study, our findings provide 
further support for the hypothesis proposed by Hellman and colleagues, that intrachromosomal 
gene amplification in the form of an hsr may occur by chance due to the location of the amplified 
genes relative to a CFS.  Further studies are needed to determine a role, if any, for other fragile 
sites flanking the 11q region in the gene amplification process.   
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 APPENDIX A.  CELL CULTURE PROTOCOLS 
 
 
M10 medium recipe 
 
 
500 mL Minimum essential medium w/ Earle’s salts + L-glutamine (#11095-081; GIBCO) 
55 mL Fetal Bovine Serum (#16000-044; GIBCO) for 10% final concentration 
5 ml Non-essential amino acids 10 mM stock (#11140-019; GIBCO)  
5.55 mL L-glutamine 200 mM stock (#9317; Irvine Scientific) 
694 µL Gentamicin (#9354; Irvine Scientific) 
 
Mix together and sterilize through 0.2 micron filter ((# SLGP033RS, Millipore, Bedford, MA) 
Aliquot and freeze at -20ºC 
 
 
Thawing OSCC cells 
 
1.  Add 1 mL pre-warmed M10 medium to 15 mL conical tube 
2.  Allow cryovial to thaw quickly in 37ºC water bath (15 sec) 
3.  Add cells to tube containing M10 medium 
4.  Spin cells at 5ºC for 5 min at 1000 x g 
5.  Remove supernatant 
6.  Resuspend with 5 mL fresh M10 medium 
7.  Place in T25 flask with cap loosened 
8.  Place flask in incubator (5% CO2 in air) at 37ºC 
 
 
Passaging OSCC cells
 
1.  Remove old medium 
2.  Wash cells in 1XHBSS (#9228; Irvine Scientific) 
3.  Add 1.5 mL 1Xtrypsin-EDTA (#9341; Irvine Scientific) to each T25 
             3.0 mL                                                                               T75 
4.  Place flask in 37ºC incubator for 1 min 
5.  Check flask for detached cells, agitating flask if cells still adherent 
6.  Once detached, add equal volume of M10 medium to flasks 
7.  Split cells into desired number of flasks and add M10 medium to 5 mL for T25  
     flask or 10 mL for each T75 flask (make sure to note passage number on flasks) 
8.  Return flasks to 37ºC incubator 
 
Freezing OSCC cells
 
Prepare the freezing medium: 
9 mL M10 medium complete 
        + 1 mL DMSO for 10% final concentration (# D128-500; Fisher Scientific) 
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Mix together and sterilize through “DMSO safe” 0.22 micron filter (Millipore) 
1.  Remove the old medium 
2.  Wash the cells with 1XHBSS 
3.  Add trypsin to the flask and place the flask in a 37ºC incubator for 1 min 
4.  When cells become detached, add an equal volume of M10 complete medium to inactivate the  
      trypsin 
5.  Place the cells in a 15 mL conical tube 
6.  Spin for 5 min at 1000 x g 
7.  Remove the supernatant by aspiration 
8.  Break up the pellet 
9.  Add 1 mL of freezing medium to the tube, resuspending the pellet 
10. Place in a cryovial, making sure to label the vial with cell line information, passage number, 
       initials, and date 
11. Place the cells in the -80ºC freezer for 2 h, then store -135ºC or in liquid nitrogen vapor    
      phase 
 
 
Normal peripheral blood lymphocyte set up for chromosome analysis 
 
1. Prewarm the peripheral blood complete medium to 37ºC in a waterbath 
2. Working in the tissue culture hood, aliquot PB Max™ peripheral blood complete medium   
    (#12557-013, GIBCO) into 5 mL per 15 mL conical tube 
3. Invert the tube several times  
4. Working in the tissue culture hood, aliquot the peripheral blood complete medium with 5 mL  
     per 15 mL conical tube 
5. Use a sterile gauze to remove the cap of the green top tube 
6. Using a sterile glass Pasteur pipette, add 13-15 drops of blood to each culture tube  
7. Cap each tube, inverting each several times  
8. Place the tubes in a slant culture rack and incubate the tubes for 72 h at 37ºC  
 
 
Protocol for inducing CFS in peripheral blood cells 
 
1. Follow steps 1-7 in “Normal peripheral blood lymphocyte set up for chromosome analysis.” 
2. Place the tubes in a slant culture rack and incubate for 48 h at 37º 
3. Add aphidicolin (APC) to blood cultures (see next page) 
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 APC stock solution:  
 
APC, 1 mg powder (Aphidicolin Nigrospora sphaerica, #A0781, Sigma, St. Louis, MO) 
Stock 1: 1 mg APC in 14.8 mL DMSO; filter sterilize and store at -15ºC 
Stock 2: 1 mL Stock 1 in 9 mL RPMI 1640 (#9140, Irvine Scientific); filter sterilize and 
store at -15ºC 
 
4. Add 100 µL of Stock 2 to each culture (0.4 µM) 
5. Invert the tubes and return them to the slant culture rack.  Incubate the cultures for 26 h at 
    37ºC  
6. Add caffeine 
 
Caffeine stock solution: 
 
Caffeine (#C0750; Sigma) 
1.942 g in 100 mL RPMI (100 mM), filter sterilize 
 
7. Remove 250 µL from each blood culture, replacing it with 250 µL caffeine solution 
8. Invert the tubes and return them to the slant culture rack.  Incubate the cultures for 6.5 h at 
    37ºC 
9. Harvest the cells (NOTE: Colcemid™ is added for 2.5 h for CFS protocol)  
Processing chamber slides for anaphase bridge analysis 
 
1.  Refer to steps 1-5 in “Passaging OSCC cells”  
2.  Add the appropriate amount of M10 medium to dilute the cells for 50% confluency  
     for each chamber slide 
3.  Add 0.5 mL of the diluted cell pellet to each chamber slide 
4.  Incubate the chamber slides for 1 hr at 37ºC  
5.  Carefully flood the chamber slides with 1.5 mL pre-warmed M10 medium 
6.  Return the chamber slides to 37ºC incubator until the cells reach 70% confluency 
7.  Remove the M10 medium and replace it with fresh M10 medium 
8.  Add 5 µL  (# 9311; Irvine Scientific) to each chamber slide  
9.  Cover each chamber slide and agitate tomix 
10. Incubate chamber slides at 37ºC for 18 h (overnight) 
11. Remove the medium and wash the chamber slides two times with fresh M10 to remove the   
      Colcemid™ 
12. Add 2 mL of fresh M10 medium to each chamber slide 
13. Incubate the chamber slides at 37ºC for 2 h (NOTE: Cell cycles will vary for each tumor  
      type; this protocol was optimized for SCC cultures.  The timing in this step may need to be  
      increased or decreased depending on specimen) 
14. Remove the medium by aspiration 
15. Remove the chamber from the chamber slide 
16. Place the slides in a fresh fixative solution (3:1 methanol:acetic acid) for 30 min 
17. Dry the slides with forced air 
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 18. Store the slides in the-20ºC freezer with dessicant until ready for use 
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APPENDIX B.  HARVESTING CELLS FOR CYTOGENETIC ANALYSIS 
 
 
Reagents 
 
Colcemid™ (# 9311; Irvine Scientific) 
0.075 M Hypotonic KCl (0.056g KCl in 100 mL dd H O) 
Cold, 3:1 Methanol:acetic acid fixative (Prepare and place in -20ºC freezer)   
M10 medium (for OSCC cell lines, see Appendix A) 
1X trypsin/EDTA (for OSCC cell lines) (#9341; Irvine Scientific) 
1X HBSS (for OSCC cell lines) (#9228; Irvine Scientific) 
2
 
Peripheral blood harvest 
 
1.  Add 50 µL of Colcemid™ (# 9311; Irvine Scientific) to each 5 mL culture (10 µg/mL) 
2.  Invert the tubes and incubate at 37ºC for 25 min (NOTE: For APC cultures, incubate for              
     2.5 h) 
3.  Place tubes in centrifuge tubes for 7 min at 1200 x g 
4.  Remove the supernatant by aspiration, leaving approximately 1.5 ml in each tube 
5.  Resuspend the pellets by tapping the tubes 
6.  SLOWLY, add 5 mL pre-warmed 0.075M KCl.  Begin adding hypotonic solution dropwise to  
     each pellet, tapping LIGHLY 
7.  Invert the tubes one time 
8.  Incubate the tubes at 37ºC in a waterbath for 18 min 
9.  Add 5 -10 drops of cold fixative to each tube, inverting one time 
10. Place tubes in centrifuge tubes for 7 min at 1200 x g 
11. Remove the supernatant by aspiration, leaving approximately 1.5 ml in each tube 
12. Resuspend the pellets by tapping the tubes 
13. Add cold fixative to 7 mL, invert each tube one time 
14. Centrifuge the tubes for 15 min at 1200 x g 
15. Remove the supernatant by aspiration, leaving approximately 1.5 ml in each tube 
16. Resuspend the pellets by tapping the tubes 
17. Continue steps 13-16 until the pellet is white and the fixative is clear 
18. Centrifuge the tubes for 5 min at 1200 x g 
19. Store the pellets in the explosion proof freezer at -20ºC until use 
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OSCC cell harvest 
 
1.  Add 50 µL Colcemid™ to each 5 mL culture (10 µg/mL) 
2.  Agitate the flasks to mix, then incubate at 37ºC for 5 h 
3.  Remove the supernatant by aspiration 
4.  Wash the cells in 1XHBSS  
5.  Add 1.5 mL of 1X trypsin-EDTA to each T25 
             3.0 mL                                                T75 
6.  Place the flasks at 37ºC for 1 min 
7.  Check each flask for cell detachment, agitating the flask if cells are still adherent 
8.  Once detached, add an equal volume M10 medium to inactivate the trypsin 
9.  Place cells in a 15 mL conical centrifuge tube 
10. Centrifuge the tubes for 7 min at 1000 x g 
11. Remove the supernatant by aspiration, leaving 1.5 ml in each tube 
12. Resuspend the pellet 
13. SLOWLY, add 5 mL of pre-warmed 0.075M KCl dropwise to each pellet, tapping 
      LIGHTLY 
14. Incubate the tubes at 37ºC in a waterbath for 21 min 
15. Add 5 -10 drops of cold fixative to each tube, inverting once 
13. Add cold fixative to 7 mL, invert each tube one time 
14. Centrifuge the tubes for 15 min at 1200 x g 
15. Remove the supernatant by aspiration, leaving approximately 1.5 ml in each tube 
16. Resuspend the pellets by tapping the tubes 
17. Continue steps 13-16 until the pellet is white and the fixative is clear 
18. Centrifuge the tubes for 5 min at 1200 x g 
19. Store the pellets in the explosion proof freezer at -20ºC until use 
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APPENDIX C.  G-T-G BANDING PROTOCOL 
 
 
Reagents 
 
1XPBS (# 9242; Irvine Scientific) 
Giemsa stain (# G3032; Sigma, St. Louis, MO) 
Gurr’s buffer (# 33199-2P; Biomedical Specialties (800-269-1158)) 
0.25% trypsin (# 15050-65; GIBCO) 
Fetal Bovine Serum (# 16000-044; GIBCO) 
 
1.  Prepare five coplin jars: 
                                              Jar 1:  5 mL 0.25 % trypsin + 60 mL 1XPBS 
                                              Jar 2:  2 mL FBS + 60 mL 1XPBS 
                                              Jar 3:  60 mL 1XPBS 
                                              Jar 4:   4 mL Giemsa stain + 60 mL Gurr’s buffer 
                                              Jar 5:   60 mL Gurr’s buffer 
 
2. For OSCC cell lines, place the slides in Jar 1 for 45 – 55 sec 
    Peripheral blood cells,                          1 min 15 sec – 1 min 30 sec 
 
3. Blot the slides on a paper towel, then place slides in Jar 2 for 10 sec 
 
4. Blot the slides on a paper towel, then place slides in Jar 3 for 10 sec 
 
5. Blot the slides on a paper towel, then place slides in Jar 4 for 4 min 
 
6. Blot the slides on a paper towel, then place slides in Jar 5 for 1 min 
7. Blow dry the slides with forced air.   
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APPENDIX D.  PREPARATION OF BAC DNA FOR FISH PROBES 
 
  
Preparation of BAC plates 
 
Adapted from (SAMBROOK et al. 1989). 
 
Reagents 
 
975 L dd H20 
25 g Bouillon LB (Luria-Bertani), Miller (DIFCO, Becton-Dickinson) 
7.5 g Bacto-Agar (DIFCO) 
Autoclave 
 
1.  Place the autoclaved LB agar for plates in a 55ºC waterbath until ready to prepare the plates 
2.  When the medium is cool to touch, add the appropriate antibiotic 
 
          For Rocchi probes or BACs requiring ampicillin (# A0166; Sigma): 
 
                                     0.005 g ampicillin in 100 mL sterile water (50 µg/mL stock)  
                                     For plates, 50 mL agar solution + 40 µL ampicillin stock 
 
          For BACs requiring chloramphenicol (# C3175, 100 mg; Sigma): 
 
                                     0.01 g chloramphenicol in 100 mL sterile water (100 mg/mL stock) 
                                     For plates, 1 L LB broth + 240 µL chloramphenicol stock 
 
3. Pour the plates and allow them to set (they may be left on the bench at room temperature  
    overnight) 
4.  Streak the plates with desired BAC 
5.  Place the plates inverted in the warm room overnight 
6.  Remove the plates from the warm room approximately 16 h after culture initiation (Individual 
     colonies should be visible) 
7.  Seal the plates with parafilm and store inverted at 4ºC for 1 week 
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Establishment of BAC cultures 
 
1.  Prepare one 15 mL conical tube per BAC by adding 5 mL autoclaved LB broth + appropriate 
     antibiotic* 
2.  Select a single colony from the BAC plate and add it to the tube, stirring.  Cap the tube. 
3.  Vortex the tube to mix 
4.  Loosen the cap, but tape the cap to the lip of the conical tube to ensure it is secure 
5.  Place the tube on a shaker in the warm room overnight 
 
*For maxi preps, initiate 35 ml LB broth + antibiotic with 5 mL of grown BAC and place in  
  warm room overnight   
 
NOTE: Grown BACs may be refrigerated up to one week prior to extraction 
 
 
General BAC extraction protocol 
 
Reagents 
 
STET: (ADD IN ORDER) 
8 g sucrose + 40 mL dd H 0 
5 mL of 1 M Tris base, pH 8.0  
5 mL Triton X-100 (t-octylphenoxypolyethoxyethanol; T9284; Sigma) 
50 mL dd H 0 
2
2
1.8612 g EDTA 
 
NOTE: There is no need to pH if the Tris base used is 8.0.  Store at room temperature  
             indefinitely 
 
10% SDS:10 g SDS in 100 mL dd H20  
then 
   880 µL dd H20 
     20 µL 10 N NaOH 
+ 100 µL 10% SDS 
 
7.5 M Ammonium acetate 
Phenol:chloroform solution 
Isopropanol 
TE / RNase A: 
 
STOCKS: 100 µL 100X TE (T9285; Sigma) in 9.9 mL dd H20 
                        RNase A, 100 mg/mL (#1007885; Quiagen) 
  1 µL RNase in 1 mL 1X TE, vortex 
  Store at 4ºC for 4 months 
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 Extraction Procedure 
 
1.  Put 1 mL of grown BAC in a 1.5 mL Eppendorf tube 
2.  Centrifuge at high speed, 15 min 
3.  Remove the supernatant, drying the inside of the Eppendorf with a kimwipe 
4.  Resuspend the pellet in 100 µL STET 
5.  Add 200 µL SDS solution to each tube. 
6.  Gently invert each tube six times.  Leave the tubes at room temperature for 5 min  
     (test with a pipette tip to see if the solution has become“stringy”) 
7.  Add 150 µL 7.5 M ammonium acetate to each tube, then gently invert each tube six times 
8.  Place the tubes on ice for 5 min 
9.  Centrifuge at high speed, 20 min 
10. Remove the supernatant with a micropipettor and place the solution in new tubes (should  
      have ± 400 µL) 
11. Under a fume hood, add an equal volume (eg. 400 µL) of phenol:cholorform, then gently  
      invert each tube six times 
12. Centrifuge the tubes in an Eppendorf microcentrifuge at 14,000 x g for 15 min 
13. CAREFULLY remove the supernatant and put it in a new tube (DO NOT disturb the bottom  
      organic layer- if this happens, be SURE to recentrifuge before proceeding)  
14. Add 0.6x the volume of isopropanol (here, 240 µL), gently invert each tube six times 
15.  Centrifuge the tubes in an Eppendorf microcentrifuge at 14,000 x g for 15 min 
16. Decant the supernatant 
17. Add an equal volume from step #10 (here, 400 µL) of COLD 70% EtOH; make sure that the 
      pellet is floating in the ethanol 
18. Centrifuge the tubes in an Eppendorf microcentrifuge at 14,000 x g for 15 min 
19. Remove the EtOH and bake the tube at 60ºC until just dry (30 sec) 
20. Resuspend the pellet in 15 µL TE/RNAse 
21. Run a 1XTAE gel to determine the DNA concentration 
 
 
BAC glycerol stock preparation 
 
   150 µL autoclaved glycerol 
+ 850 µL culture grown in LB broth + antibiotic (prior to extraction) 
 
 
Labeling BAC for fluorescence in situ hybridization (FISH) 
 
Reagents
 
Vysis nick translation kit (# 32-801-300, Vysis, Downers Grove, IL) 
50 nmol Spectrum Orange-dUTP™ (# 30-803-000, Vysis)  
   Working solution: 33 µL in sterile water (0.6 µm) 
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50 nmol Spectrum Green-dUTP™ (# 30-803-200, Vysis) 
Diethylaminocoumarin-5-dUTP213 (DEAC213; Perkin Elmer Life and Analytical Sciences, 
    Inc.) NOTE: Reagent must be special ordered at 10 mM concentration.  
 
   For nick translation, use 2.0    µL of 10 mM stock 
               + 55.14  µL of sterile endonuclease free H2O 
   Working solution is 0.35 mM DEAC213 
 
BACs labeling with Vysis nick translation kit 
 
 17.5 µL extracted BAC DNA 
   2.5 µL 0.2 mM Spectrum Green-dUTP™, Spectrum Orange-dUTP™ or 0.35 mM 
               DEAC213 
   5.0 µL 0.1 mM dTTP 
 10.0 µL dNTP mix 
   5.0 µL 10X nick translation buffer 
         + 10.0 µL nick translation enzyme  
  
Precipitation of labeled BAC DNA for FISH 
 
Reagents 
 
Human Cot-1 DNA, 500 µL (# 1581074; Roche Molecular Biochemicals, 800-262-1640) 
Human placental DNA (# D3287, 10 µg/µL; Sigma) 
Working: dilute 9 µL in 91µL sterile H20 
Sterile H20 
Cold, 100% EtOH 
3 M sodium acetate (NaOAc), ph 5.5 (# S7899; Sigma) 
Hybridization buffer: 10.0 mL molecular biology grade formamide (# F9037; Sigma) 
                                 +  0.2 g    dextran sulfate in 10 mL 4XSSC 
                                  pH to 7, store in aliquots 
 
1. Add the reagents in order 
    Follow the general scheme of: 
 
             158.0 µL DNA 
               12.1 µL Cot-1 
           + 57.5 µL pDNA 
Total of the above x 0.1 equals the amount of NaOAc to add 
Add the amount of NaOAc to the total volume of the solution 
Total volume of the solution x 2.5 equals the amount of 100% EtOH to add 
 
2. Mix the solution by pipetting 
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 3. Place the tube in -135ºC freezer for 30 min 
4, Centrifuge the tubes in an Eppendorf microcentrifuge at 14,000 x g for 15 min 
5. Remove the supernatant and dry the inside of the tube with a kimwipe, being careful not to  
    touch the pellet 
6. Use forced air to lightly dry the pellet  
7. Bake the tube at 60ºC for 5 min 
8. Resuspend the pellet in 3 µL sterile water + 7 µL hybridization buffer for each slide area 
9. Place the tube on a 37ºC shaker until ready to denature (see Appendix E) 
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APPENDIX E.  FLUORESCENCE IN SITU HYBRIDIZATION PROTOCOL 
 
 
Reagents 
 
20XSSC:  175.3 g NaCl (BP358-212; Fisher) 
                  88.2 g Sodium citrate (S279-3; Sigma) 
                  800    mL dd H20 
pH to 7, add 200 mL dd H20 
Autoclave 
 
2XSSC :   100 mL 20XSSC 
              + 900 mL dd H20 
       pH to 7 
       preheat 190 mL to 37ºC in water bath  
 
RNase A    (# R5503, 1g; Sigma) 
 
    Stock: Add 5 mL 2XSSC to the powder 
               Aliquot in Eppendorf microfuge tubes, 1 mL per tube 
    Store at -20ºC 
 
    Working: Dilute 1 mL of stock solution into 99 mL of 2XSSC in a glass bottle (or two, 50 mL  
                    conical centrifuge tubes)and lightly cap  
                    Place the solution in a beaker of water within a waterbath at 100ºC (CRITICAL) 
                    Aliquot into 2.5 mL tubes and store the tubes at -20ºC 
                    For FISH, use one tube of working solution in 37.5 mL of 2XSSC, etc. 
 
70% Formamide       140 mL Formamide (# BP227-500, Fisher Scientific) 
     40 mL 20XSSC 
                      + 20 mL dd H20 
   pH to 7 
   preheat to 75ºC in a waterbath 
 
Ethanol series: 70%, 80%, 100% 
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 FISH Reagents (continued) 
 
DAY 2, WASH 1: 0.4XSSC / 0.3% Tween 20  (polyoxyethylenesorbitan monolaurate; P5927; 
Sigma) 
 
20 mL 20XSSC 
950 mL dd H20 
3 mL Tween 20 
 dissolve, pH to 7, add 27 mL dd H20 
  preheat to 72ºC in a waterbath 
 
DAY 2, WASH 2: 2XSSC / 0.1% Tween 20 
  
100 mL 20XSSC 
850 mL dd H20 
    1 mL Tween 20 
 
dissolve, pH to 7  + 49 mL dd H20 
 
DAPI (25 mg) (Sigma) 
 
    Stock:   100 mL 20XSSC 
                 850 mL dd H 
                     1 mL Tween 20 
    
    Working:  40  µL DAPI stock 
                     + 50 mL 2XSSC    
 
Antifade: PPD (# 13-169-3, 25 g; Fisher Scientific) 
 
    Working:0.15 g PPD in 15 mL 1XPBS 
     pH to 8, sterile filter 
     add 35 mL glycerol (final pH= 7.5) 
     Store in aliquots at -20ºC 
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 FISH DAY 1 
 
 
1. Prewarm the 2XSSC solution + RNAse aliquots to 37ºC and the 70% formamide solution to  
    75ºC 
2. Add the RNase to the 2XSSC, and mix with a glass Pasteur pipet 
3. Place the slides in RNase / 2XSSC for 30 min 
4. Wash the slides 3 x 2 min in 2XSSC, at room temperature 
5. Dehydrate the slides in a graded ethanol series, 70, 80, 100 for 2 min each 
6. Allow the slides to air dry 
7. Denature the probes at 72ºC for 5 min 
8. Preanneal the probes at 37ºC in a waterbath for a maximum of 30 min 
9. Denature the slides in the 70% formamide solution for 1 min 50 sec 
10.Dehydrate the slides in a graded ethanol series, 70, 80, 100 for 2 min each 
11. Place the slides on a 55ºC slide warmer 
12. Add the probe to each slide and coverslip 
13. Seal the coverslips with rubber cement 
14. Place the slides in a 37ºC hybrization chamber overnight  
 
 
 
FISH DAY 2 
 
 
1. Remove the rubber cement and peel off the coverslips 
2. Place the slides in 0.4XSSC/0.3% Tween 20 at 72ºCfor 2 min  
3. Place the slides in 2XSSC/0.1% Tween 20 for 2 min at room temperature 
4. Rinse the slides in 2XSSC at room temperature 
5. Place the slides in the DAPI solution, 1 min 
6. Rinse slides in water 
7. Do not allow slides to dry.  Add antifade solution to the slide 
8. Coverslip the slide and seal with clear nail polish 
9. Store slides at -20ºC 
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APPENDIX F.  FLEXSTAB ANALYSIS PROTOCOL 
 
 
1. Install the program on UNIX as instructed at  
    (http://leonardo.ls.huji.ac.il/departments/genesite/faculty/bkerem.htm).§   
2. Save the input sequence file starting with “..” at the first line in the same folder 
3. Run the FlexStab program with the following parameters: 
    File name 
    Choose GCG format (option 1) 
    Window size = 100 
    Shift increment (1) 
    Graphic output (option 1) 
    Output file name (name output file here) 
    Type of analysis (option 2) 
    The program will then run 
4. Upon completion, there should be an output file consisting of data points.  Usually, the  
    number of data points is equal to the size of the DNA sequence (eg. 1000 bp DNA sequence   
    will have numeric output file of 1000 data points). 
5. Run a simple statistics analysis including the mean of the data value and standard deviation  
    (SD) of the values (created by Xin Huang, Ph.D., Dept. of Human Genetics, University of  
    Pittsburgh) 
6. Choose data points that are higher than 4.5 SD as significant flexibility peaks (see Morelli et  
     al., 2002) 
7. Count the number of continuous data points in the output file for the number of total peaks 
8. To get the AT/GC content, replace AT/GC in the sequence file 
9. Count the number replaced 
10. Calculate the total percent 
 
 
 
 
 
 
 
 
§  FlexStab analysis carried out with the assistance of Mr. Ryan Evans and Dr. Xin Huang (Dept. of Human  
     Genetics, University of Pittsburgh).     
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APPENDIX G.  FLEXSTAB RESULTSˆ
 
 
ˆ  Output from FlexStab analysis program run on the FRA11F sequence.  Arrows represent regions of high  
   flexibility. (A) 0-342 kb; (B) 342 kb- 673 kb; (C) 673 kb- 1 Mb; (D) 1 Mb- 1.3 Mb; (E) 1.3 Mb- 1.67 Mb;  
   (F) 1.67 Mb- 2 Mb.  (G) 2.0 Mb- 2.3 Mb; (H) 2.3 Mb- 2.67 Mb; (I) 2.67 Mb- 2.98 Mb; (J) 2.98 Mb- 3.32 Mb;  
   (K) 3.32 Mb- 3.65 Mb; (L) 3.65 Mb- 3.98 Mb.  Note sequence gap (large arrow, J) of approximately 12 kb   
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APPENDIX H.  COMPOSITE KARYOTYPES OF PARENTAL AND CLONED  
UPCI:SCC CELL LINES 
 
Cell line Composite Karyotype§
 
 
 
 
UPCI:SCC040p16 
60-75,XXY,-X[3],der(1)t(1;10)(p13;?)x2[2],der(1)t(1;10)(q21;?)[4],+der(1)t(1;10) 
(q21;?)[4],-2,-2[3],der(3)t(3;10)(p11;q11)x3[2],+der(3)t(3;10)(p11;q11)x2[2],+i(3)(q10) 
[2],-4[3],der(4)t(4;5)(q25;q22)[4],i(5)(p10)[4],+der(6)t(5;6)(?;q10)x2[2],+der(7)t(7;14) 
(p13;q11.2)[2],der(8)t(8;13)(p23;q22)[2],+der(8)t(8;13)(p23;q22)[2],der(9)t(9;19)(p10;?)x2[2],
+der(9)t(9;19)(p10;?)[2],der(10)t(10;20;10)(?;?;?)[4],der(10)t(10;20)(?;?)x2[2], 
+der(10)t(10;20)(?;?)[2],-11[4],del(11)(q13)hsr(11)(q13)x2[4],-13,-13[4],-14,-14,-14[3], 
-15[4],-17[3],der(18)t(14;18)(q11.2;q11.2)[4],+der(18)t(14;18)(q11.2;q11.2)[4],-19[4], 
+der(20)t(16;20)(q13;q11.2)[2],-21[4],der(21)t(Y;21)(q12;q22)[3],-22[3][cp4] 
 
 
 
UPCI:SCC040p35 
Clone A 
69-75,XX,-Y[3],der(1)t(1;10)(p13;?)x2[2],der(1)t(1;10)(p13;?)[2],+der(1)t(1;10)(q21;?) 
x2[3],der(3)t(3;10)(p11;q11)[3],+der(3)t(3;10)(p11;q11)[3],der(4)t(4;5)(q25;q22)[3],-5, 
-5[3],+der(6)t(5;6)(?;q10)[2],+der(7)t(7;13)(q11.2;q22)[3],+der(8)t(8;13)(p23;q22)[4], 
+der(8)t(8;13)(p10;q10)[2],der(9)t(9;19)(p10;?)[3],+der(9)t(9;19)(p10;?)[3],-10[3], 
der(10)t(10;20;10)(?;?;?)[3],-11[4],del(11)(q13)hsr(11)(q13)x2[4],-13,-13,-13[3],-14,-14, 
-14[3],der(15)ins(1;15)[4],-17,-17[3],der(18)t(14;18)(q11.2;q11.2)[2],+der(18)t(14;18) 
(q11.2;q11.2)x3[2],der(20)t(13;20)(q22;q12)x2[4],-21,-21[3],der(21)t(Y;21)(q12;q11.2) 
[4][cp4] 
 
 
UPCI:SCC040p35 
 
Clone B 
 
68-74,XXY,der(1)t(1;10)(p13;?)[4],der(1)t(1;10)(q21;?)[4],+der(1)t(1;10)(q21;?)[4], 
der(3)t(3;10)(p11;q11)[4],+der(3)t(3;10)(p11;q11)[4],del(4)(q31.1)[4],+der(4) t(4;5) 
(q25;q22)[3],+der(4)t(4;5)(?;q22)[2],-5[3],i(5)(p10)[3],t(5;15;10)(?;?;?)[3],+der(6) 
t(5;6)(?;q10)x3[2],der(9)t(9;19)(p10;?)x2[3],+der(9)t(9;19)(p10;?)[3],-10[3],der(10) 
t(10;20;10)(?;?;?)[4],-11[4],del(11)(q13)hsr(11)(q13)x2[4],-13,-13,-13[4],-14,-14,-14[4], 
-15,-15[3],-17[3],der(18)t(14;18)(q11.2;q11.2)x2[2],der(20)t(13;20)(q22;q12)x2[4],-21 
[4],der(21) t(Y;21)(q12;q21)x2[2],del(22)(q11.2)x2[2][cp4] 
 
 
 
UPCI:SCC131p18 
73-83,XY,-X[4],-2[4],der(3)t(3;16)(?;?)[2],t(3;16)(q21;p13.1)[2],-4,-4[5],del(4)(?)[5], 
der(5)t(5;7)(q31;p13)x2[2],-6[3],+der(7)t(X;7)(p11.2;p11.2) [2],+der(7)t(5;7)(?;?)x2[2], 
+der(7)t(5;7)(?;?)[2],+der(8)t(3;8;13)(?;?;?)x2[2],+der(8)t(3;8;13)(?;?;?)[2],der(9)t(9;14) 
(p21;q12)[2],+der(9)t(9;14)(p21;q12)x2[2], der(10)t(2;10)(p10;q10)x2[2],+der(10) 
t(2;10)(p10;?)[2],del(11)(q13)hsr(11)(q13)[3],der(?)t(4;11)(?;?)[2],+der(11)t(4;11;17) 
(?;q13;?)x2[5],+der(?)t(4;11;17)(?;?;?)x2[4],-12[3],+13[2],-14,-14[3],der(17)t(2;17) 
(q21;q21)[5],+der(17)t(2;17)(p13;p11.2)[2],+19[2],del(20)(q11.2)[2],-21[5],-22[3], 
del(22)(q11.2)x2[5][cp5] 
 
UPCI:SCC131p33 
 
Clone C 
72-78,XY,-X[3],+Y[2],der(3)t(3;16)(q21;?)[2],der(3)t(3;16)(?;?)x2[2],-4[3].del(4)(?)[2], 
-5[3],+der(7)t(5;7)(?;?)[2],+der(8)t(3;8;13)(?;?;?)[2],der(9)t(9;14)(p21;q12)[2],+der(9) 
t(9;14)(p21;q12)[2],+der(9)t(9;14)(?;?)x2[2],+der(10)t(2;10)(p10;?)[3],+der(11)t(4;11;17) 
(?;q13;?)[3],+der(?)t(4;11;17)(?;?;?)x2[2],-14[3],+der(17)t(2;17)(q21;q21)[3],+20[2], 
+del(20)(q11.2)[2],-22[3][cp3] 
 
UPCI:SCC131p30 
 
Clone D 
56-82,XY,-X[3],+Y[3],+1[2],-2[4],-3,-3[3],-4,-4[4],del(4)(?)[3],-5[4],-6[4],der(9)t(9;14) 
(p21;q12)[2],+der(9)t(9;14)(p21;q12)x3[2],+der(9)t(9;14)(p21;?)[2],+der(9)t(9;14)(?;?) 
x2[3],+der(10)t(2;10)(p10;?)x2[2],der(?)t(4;11)(?;?)[2],+der(11)t(4;11;17)(?;q13;?)x2[4], 
+der(11)t(4;11;17)(?;q13;?)x2[3]†,+der(?)t(4;11;17)(?;?;?)x2[3],-13[3],-14,-14[3],-15[3],-16 
[4],-17[3],der(17)t(2;17)(q21;q21)[2],+20[2],-22,-22[3],del(22)(q11.2)[2][cp4] 
 
§  Rearrangements in bold face print represent abnormalities unique to an individual cell line. If not highlighted,  
   similar aberrations were observed in other cell lines of similar lineage, but could not be included in the composite  
   karyotype due to the number of cells analyzed.   
†  Different chromosome segments with unknown breakpoints. 
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APPENDIX I.  CORRELATION OF CCND1 GENE AMPLIFICATION AND  
                      ANAPHASE BRIDGES 
 
 
 
 
 
 
 
 
Nonparametric Spearman correlation coefficient analyzing the percent anaphase bridges 
compared to percent of cells w/ > 10 copies: 0.40; p-value= 0.037¶.
 
¶   Statistical analysis carried out by Doug Potter, Ph.D. (University of Pittsburgh Cancer Institute). 
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